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All cancers have deregulated cell proliferation. Therefore, full understanding of 
cell cycle control is needed to identify protein targets that can lead to the 
development of novel therapies, as well as improving our knowledge and use of 
existing ones. Greatwall kinase (GWL), a protein essential for mitotic entry in 
human cells, is gaining interest in cancer research as it has been shown to be 
upregulated in various cancers. My research aims to decipher the mechanisms 
of Triple Negative breast cancer (TNBC) cell sensitivity to GWL knockdown, as 
this information could provide scope for the development of novel drugs to be 
synergised with existing treatments. We have shown that depletion of GWL via 
shRNA in certain TNBC cell lines causes harmful cell proliferation defects. 
Surprisingly these effects coincided with significant depletion of replicating cells, 
rather than pronounced mitotic defects. This suggests that certain cancer cells 
are especially reliant on GWL and that GWL may have other functions apart 
from its known role in suppressing mitotic PP2A activity. To further investigate 
these novel functions, we have performed a siRNA cell viability screen 
comparing cells lacking and expressing GWL. This led to the identification of a 
novel synthetic lethality between CDK4 (a kinase whose activity is restricted to 
G1-S phase) and GWL (canonically active in mitosis). Further analysis revealed 
that this synergy of GWL and CDK4 does not involve the known downstream 
substrates of GWL: ENSA and ARPP19, suggesting that GWL acts in this 
pathway in a non-canonical way. Taken together, this thesis presents the 
discovery of a novel biological pathway in the control of the G1/S transition that 
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Chapter 1. Introduction 
	
1.1 The mammalian cell cycle 
	
The cell is the fundamental building block of all living things. With the exception 
of the very first cells on Earth around 3.5 billion years ago, all cells have arisen 
from other cells via cell division. The first description of the cell is generally 
credited to Robert Hooke who, whilst studying a slice of cork under a 
microscope, noted small and regular units that he described were like an 
empty honeycomb, or the cells monks would sleep in at that time (W. Turner 
1890; Mazzarello 1999). The discoveries and contributions of many scientists, 
including Louis Pasteur, Robert Remak, Rudolf Virchow, Matthias Schleiden 
and Theodor Schwann, together led to the disproval of Spontaneous 
Generation Theory, and the wide acceptance of Cell Theory. 
 
Cell division can create new cells in two slightly different ways. The word 
mitosis describes a cell division in which a single cell duplicates its DNA (and 
organelles, if the cell possesses these) and divides once to create two identical 
cells. This process is used in asexual reproduction, and for growth and repair in 
multicellular organisms. The other type of cell division is meiosis, which is 
exclusively used to create gametes by organisms that reproduce sexually. In 
meiosis, chromosomal crossover followed by two cell divisions creates four 
genetically different cells. The process that co-ordinates these highly complex 
cell division events is the cell cycle, and in this thesis, I will be focusing on the 
mitotic cell cycle.  
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The fundamental task to allow cellular proliferation is ensuring accurate genome 
duplication and segregation of the duplicated genome. In bacteria there is no 
strict separation of these two processes, but the evolution of a separate nuclear 
compartment in eukaryotes appears to have necessitated the introduction of an 
ordered sequence of events termed the cell division cycle. In most animal cells 
the typical progression of this cycle involves the separation of the DNA 
synthesis phase (S phase) by two ‘gap’ phases (G1 and G2) from the 
segregation and division phase (M phase, mitosis). The stages comprising of 
G1, S and G2 phases can also be referred to as interphase (Howard & Pelc 
1986). During interphase, a cell co-ordinates and interprets signals from its 
environment and may receive sufficient pro-growth signals to enter a new round 
of mitosis, which means the cell will prepare to synthesise a copy of its DNA, 
and this phase is termed G1. DNA replication takes place in S phase, and G2 is 
the second gap phase in which cells check that DNA replication has been done 
properly and prepares to begin mitosis (Alberts et al. 2002; Morgan 2007). 
Although mitosis is the shortest of the cell cycle phases, it is so dynamic in 
nature that the mitotic phase can be further divided into several additional 
phases: Prophase, in which the nuclear envelope is broken down (Nuclear 
Envelope Breakdown, NEB) and the chromosomes begin to condense. The 
next two phases are prometaphase and metaphase, in which the mitotic spindle 
is assembled and the chromosomes line up on the equator of the cell, called the 
metaphase plate, and the sister chromatids are attached via their kinetochore to 
a spindle pole. Then in anaphase the sister chromatids are pulled and 
separated to each spindle pole, and this is followed by telophase in which a 
new nuclear envelope starts to form, and the chromosomes begin to de-
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condense. After this mitotic stage, the cell undergoes cytokinesis by pinching its 
cytoplasm and cleaving into two to form two daughter cells (Alberts et al. 2002; 
Morgan 2007).  
 
Cells decide whether or not to divide by interpreting the signals they receive 
from their surroundings. This is true for unicellular organisms such as yeasts as 
well as multicellular organisms. However, in multicellular life the cells are 
formed into tissues and organs, and so all cells must co-operate to maintain 
organisation for the benefit of the organism. Thus, almost all types of normal 
human cells will not proliferate unless prompted to do so by mitogenic factors 
(Blagosklonny 2004; Duronio & Xiong 2013). Other signalling proteins such as 
transforming growth factor-β (TGF-β), are able to overrule the pro-growth 
messages conferred by mitogenic factors and stop cell proliferation (Kubiczkova 
et al. 2012; Li et al. 2014). These conflicting signals are collected by many 
different cell surface receptors, and somehow processed into a binary decision: 
to divide, or not divide? After a round of mitosis and cytokinesis, the cell must 
decide soon after whether it will enter another cycle of division or enter a un-
proliferative state. The un-proliferative state can be reversible, which is known 
as quiescence or G0 (G zero); or it can be irreversible, which is called 
senescence and is especially associated with fully differentiated cells (Cheung 
& Rando 2013). In 1974, Pardee provided evidence for the quiescent state and 
demonstrated the existence of a restriction point (R-point) in G1 that determines 
cell fates: cells in G1 are able to become quiescent before the R-point but after 
the R-point, they are committed to enter a mitotic cell cycle. Transition of the 
restriction point has been proposed to be determined by accumulation of a 
 17 
labile protein (R-protein) whose synthesis is sensitive to growth factors, and 
must accumulate to a critical amount before a cell can pass the restriction point 
and proceed towards DNA synthesis (Campisi et al. 1982). However some 
studies suggest that both terminally differentiated and senescent cells are able 
to re-enter the cell cycle by inhibiting tumour suppressors such as p53 and RB 
(Beauséjour et al. 2003; Pajcini et al. 2010). 
 
1.2 CDKs and Cyclins 
 
A significant part of the cellular machinery that decides in G1 phase whether a 
cell enters a proliferative state, as regulating many processes throughout the 
cell cycle as a whole, is a group of serine/threonine protein kinases, collectively 
called the Cyclin-dependent kinases (CDKs). The nature of these kinases, as 
suggested in their name, is that they never act alone. They require regulatory 
subunits called Cyclins for proper function. Various CDK-Cyclin complexes are 
largely responsible for transmitting signals to hundreds if not thousands of 
targets to move the cell through growth and division, and so form the ‘engine’ or 
‘master regulators’ of the cell cycle machinery. During G1 phase, the activities 
of two CDKs – CDK4 and CDK6 are guided by the D Cyclins (D1, D2 and D3). 
After the R-point in late G1, the E Cyclins (E1 and E2) associate with CDK2 to 
enable the phosphorylation of the substrates required for entry into S phase 
(Bertoli et al. 2013). As cells enter S phase, the A Cyclins (A1 and A2) replace 
the E Cyclins as the binding partners of CDK2, allowing S phase to progress. 
Later in S phase, the A Cyclins now switch partners and bind with CDK1. As the 
cell moves further into G2 phase, the A Cyclins are replaced as the binding 
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partners of CDK1 by the B Cyclins (B1 and B2). At the start of M phase, the 
CDK1-Cyclin B complexes trigger the events that together make up the 
complex, dynamic movements of mitosis (Morgan 2007; Malumbres & Barbacid 
2009; Hochegger et al. 2008). After the metaphase–anaphase transition, Cyclin 
levels start to decline, and CDK-controlled phosphorylations begin to be 
reversed by phosphatases to drive mitotic exit (Barr et al. 2011; E. S. Johnson 
& Kornbluth 2012). The events in each phase of the cell cycle will be covered in 
more detail later. 
 
The activities of the CDK-Cyclin complexes must be modulated to have control 
over the different cell cycle stages. It is the fluctuating levels of Cyclin proteins, 
via rounds of intermittent Cyclin gene expression and proteolysis, that induce 
fluctuations in their corresponding CDK activities, as CDK protein levels remain 
fairly constant (Minshull et al. 1989; Minshull et al. 1990). Figure 1.1 
summarises this process, with panel A) indicating which CDK partners with 
which Cyclin and at what cell cycle stage, and panel B) indicating how the 
different Cyclin protein levels in the cell rise and fall during the cell cycle 
phases. 
 
The first member of the CDK family to be identified (now designated CDK1, 
especially in human cells) was discovered via genetic screens in S. 
pombe and S. cerevisiae mutants with defects in their cell division cycles 
(Russell & Nurse 1986). This protein, named Cdc2 in S. pombe and Cdc28 in S. 
cerevisiae, was shown to be essential for cell-cycle progression. Then, 
homologs of Cdc2 were identified in human cells by their abilities to rescue 
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yeast mutants (M. G. Lee & Nurse 1987; Draetta et al. 1987). Cyclins were 
discovered during studies of the sea urchin cell cycle (Evans et al. 1983; Pines 
& Hunt 1987), and are so named because their concentration within the cell 
rises and falls in a cyclical fashion throughout the cell cycle. In budding yeast, a 
single CDK termed Cdc28 drives the progression through the cell cycle by 
interacting with cell cycle phase-specific Cyclins. In higher eukaryotes, these 
functions of CDK1 have been distributed among different homologues of the 
kinase that interact with specific Cyclins at a given time and place in the cell as 
described earlier and illustrated in Figure 1.1. Studies of cell cycle control 
mechanisms across a variety of eukaryotes have found that the networks that 
underpin the cell cycle and the topology of the cell cycle control proteins are 
remarkably conserved, even if individual protein amino acid sequences can be 
very different (Cross et al. 2011). For example, the human Cdc2 can be a 
substitute for Cdc2 in Schizosaccharomyces pombe (M. G. Lee & Nurse 1987) 
and for the CDK1/CDC28 in Saccharomyces cerevisiae (Wittenberg & Reed 
1989). Also, human Cyclins can substitute for S. cerevisiae Cyclins (Lew et al. 
1991). 
 
Cyclins act as allosteric activators of CDKs. When docking with its Cyclin 
partner, the CDK protein undergoes a conformational change that rearranges 
the activation loop, or T-loop, so that the kinase’s active site is exposed. This 













































Figure 1.1 Control of the mammalian cell cycle by CDK-Cyclin complexes 
A) A schematic representation of the CDK-Cyclin complexes that regulate 
mammalian cell cycle progression throughout the different cell cycle phases. 
Activating regulators are in green boxes, inhibitory regulators are in red boxes.  
CAK is the trimer of CDK7/Cyclin H/MT1. Adapted from Malumbres et al. 2010.  
B) Cyclin expression during the cell cycle. D-type Cyclin levels are relatively 
stable throughout the cell cycle, and E-type Cyclins are expressed at G1/S to 
drive S phase entry. A-type Cyclins allow progression into mitosis from S 


























binding (Jeffrey et al. 1995; Russo et al. 1996). In contrast, Cyclins have no 
enzymatic activity but contain binding sites for substrates, in addition to the 
CDK binding site (Petri et al. 2014; Dorée & Hunt 2002). It is important to note 
that Fig. 1.1 does not tell a complete story, as firstly CDKs can be promiscuous 
in their Cyclin binding, with CDK1 and CDK2 being able to bind Cyclins A, B, D 
and E, in comparison to CDK4 and CDK6 only partnering with D-type Cyclins 
(Hochegger et al. 2008). Secondly, other post-translational modifications are 
required for a CDK’s activity to peak. In addition to Cyclin binding, an activating 
threonine phosphorylation is added by the CDK-activating kinase (CAK) 
complex, which is in itself a CDK-Cyclin complex: CDK7/Cyclin H (Fesquet et al. 
1993; Poon et al. 1993; Fisher & Morgan 1994) but also includes the ménage a 
trois 1 (MAT1) protein to form a trimeric complex (Kaldis et al. 1998). However, 
unlike most other CDK-Cyclins, CDK7/Cyclin H was found to be active 
throughout the cell cycle with no detectable oscillation in its activity (Matsuoka 
et al. 1994; Poon et al. 1994; A. J. Brown et al. 1994).  
 
In human cells, there are at least 20 different CDKs that interact with at least 29 
Cyclins and Cyclin-related proteins, though not all of them are directly involved 
in the cell cycle (Fung & Poon 2005; Malumbres & Barbacid 2009). This means 
that it is likely that there is some redundancy between the CDKs and their 
Cyclins. The most extreme examples of this are genetic studies with knock out 
mice that produced embryonic fibroblasts lacking CDK2, CDK3, CDK4 and 
CDK6 (Santamaría et al. 2007; Barrière et al. 2007). Likewise, a 2010 study 
from the Nurse lab produced a functional cell cycle in S. pombe relying on a 
single Cyclin/CDK complex (Coudreuse & Nurse 2010). From these genetic 
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studies a minimal-threshold model of cell cycle control emerged. In this model, 
the differences between the interphase and mitotic CDKs does not rely on 
substrate specificity, but simply results from a higher threshold activity for 
mitosis than for interphase (Hochegger et al. 2008). Thus, the CDK activity 
threshold appears to differentiate between cell cycle phases rather than 
substrate specificity alone. This is possibly due to the high amino acid 
sequence identity between the CDKs which may prevent failsafe substrate 
binding site specificity (for example between CDK4 and CDK6 amino acid 
sequence homology is 71% (Ferrer et al. 2006)). The evolution and 
conservation of specific CDKs in higher eukaryotes does, however, suggest 
qualitative differences between these complexes must exist that contribute to 
fitness and have therefore been conserved. CDK2, for example does not play 
any essential role for the development and life span of mice, but is essential for 
fertility (Ortega et al. 2003; Berthet et al. 2003). These qualitative functions of 
specific CDK/Cyclin complexes remain largely unexplored.  
 
1.2.1 CDK-Cyclin complexes are regulated by CDK inhibitors 
	
Another layer of cell cycle control, which occurs in G1 phase, is done through 
the Cyclin dependent kinase inhibitors (CKI). The INK4 gene family of CKIs 
encodes p16INK4a, p15INK4b, p18INK4c, and p19INK4d, all of which bind to CDK4 
and CDK6, and inhibit their kinase activities by interfering with their association 
with D-type Cyclins (Sherr & Roberts 1999). In contrast, the Cip/Kip family of 
CKIs bind to both Cyclin and CDK subunits, and can modulate the activities of 
Cyclin D-, E-, A, and B-CDK complexes (Sherr & Roberts 1999). The CKI 
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proteins play an important role as tumour suppressors. They prevent 
phosphorylation of the retinoblastoma protein (RB) in G1 until sufficient 
mitogenic signals cause increased Cyclin D expression to permit sufficient 
CDK4/6 activity that allows the cell cycle to continue (Sherr & Roberts 1999). 
The RB protein will be talked about in more detail later. The members of the 
INK4 and Cip/Kip protein families and where they act in the cell cycle are noted 
in Figure 1.1. 
 
1.3 Initiation of cell cycle entry and cell cycle checkpoints 
	
To safely navigate the complex procedure of cell division, there are rigid cell 
cycle checkpoints in place. The term ‘cell cycle checkpoint’ refers to the 
mechanisms by which a cell actively pauses cell cycle progression until it can 
ensure that an earlier process, such as DNA replication or mitosis, is 
complete (Hartwell & Weinert 1989). This means the cell cycle checkpoints act 
as a means of surveillance and protection, to ensure that genomic stability is 
maintained and to prevent aberrant cells from proliferating. Whilst these layers 
of protection are extremely effective at preventing the emergence of cancerous 
cells, it is not failsafe and misregulation or mutations in the cell cycle checkpoint 
proteins are very common in cancer cells (Malumbres & Barbacid 2009). The 
role of the cell cycle in cancer cell formation will be discussed later. Most adult 
human cells are differentiated and in a quiescent state, which occurs via hypo-
phosphorylated RB and other proteins repressing cell cycle gene expression 
through the binding and inhibition of the E2F family of transcription factors 
(Infante et al. 2008). However, quiescent cells are able to re-enter the cell cycle 
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under certain conditions. When mitogenic signalling pathway activation leads to 
the induction of Cyclin D and E expression in G1 phase, this permits the 
formation of active Cyclin -CDK4/6 and -CDK2 complexes, respectively. These 
active Cyclin-CDK molecules can then add inhibitory phosphates to RB, thus 
inactivating it.  
 
This releases the E2F transcriptional activators and allows the transcription of 
genes required for cell cycle progression to begin (Bandara et al. 1991; 
Malumbres 2011). The activation of these E2F dependent transcription 
programs is the key event that commits cells to enter the cell division cycle, and 
a schematic of this process is shown in Figure 1.2. As previously mentioned, 













Figure 1.2 Activation of E2F by Cyclin D-CDK4/6 in 
G1 phase A summary of how the transcription factor 
E2F is activated to permit the progression from G1 to S 
phase. Cdk4 or Cdk6 complexed with Cyclin D hyper-
phosphorylates RB, released E2F from RB binding. E2F 




1.3.1 G1/S transition and checkpoint 
	
If the cell has progressed past the restriction point, then this means it will 
commit to replicating its DNA even if the mitogenic growth factors are removed 
from the environment (Elledge 1996). Recent work by the Meyer lab has 
redefined this commitment point as the inactivation of the APC/Cdh1 ubiquitin 
ligase that is activated at the end of mitosis, and maintains Cyclin degradation 
until it is turned off in mid G1 phase (Cappell et al. 2016). The restriction point, 
also known as the G1/S checkpoint, operates to monitor the transition between 
the quiescent or G0 phase, and the proliferative state. This checkpoint 
assesses whether a cell is ready to enter S phase and replicate the genome, by 
monitoring for the presence of growth factors and DNA damage. During the 
entirety of the cell cycle the DNA damage response (DDR) will be constantly 
monitor for and detect DNA damage; and will only allow the cell cycle to 
progress if conditions are acceptable. The DNA damage checkpoint can arrest 
the cell cycle in mid S phase or in late G2 phase (Y. Zhu et al. 2004; Ciccia & 
Elledge 2010; Heijink et al. 2013).  
 
Several mechanisms have evolved to prevent cell cycle progression once this 
checkpoint is activated. The major pathway relies on the p53 tumour suppressor 
that induces the transcription of p21, thereby preventing CDK activation and 
origin firing (He et al. 2005). However other mechanisms, such as the regulation 
of the CDK2 Y15 dephosphorylation by Cdc25A (Gu et al. 1992), also appear to 
play a role but are less well understood. A key effector of the G1/S checkpoint is 
DNA damage, but other factors such as cell size, metabolism and cellular stress 
 27 
signalling may also result in activation of this pathway (Barnum & O’Connell 
2014). 
 
The major events past this point that lead to the initiation of S phase concern 
mainly the licensing and firing of DNA replication origins, which are initiated 
during G1 phase (Araki 2010; Yekezare et al. 2013). DNA replication starts from 
defined genomic regions termed origins. In bacteria, DNA replication generally 
initiates at a single, well-defined origin on a circular chromosome. In contrast, 
eukaryotic cells replicate their genomes from multiple origins that are distributed 
on multiple chromosomes (Yekezare et al. 2013). Replication origins are 
sequence specific in budding yeast, but appear to be only loosely defined in 
higher eukaryotes (Goldar et al. 2009; Barberis et al. 2010). To guide DNA 
synthesis, the origins of replication are bound by the Origin Recognition 
Complex (ORC), which serves as a foundation for the assembly of the pre-
replication complex (pre-RC) which is comprised of the Mcm2-Mcm7 complex 
and the licensing factors Cdt1 and Cdc6 (H. Rao & Stillman 1995; Rowley et al. 
1995; Speck et al. 2005). This reaction can only occur during a period of low 
CDK activity, thereby preventing relicensing after CDK activity rises, until the 
cell cycle is complete and Cyclins are degraded at the end of M phase 
(Hochegger et al. 2008). Origin firing involves the activation of the Mini-
Chromosome Maintenance (Mcm) complex that leads to a melting of the DNA 
strands allowing the initiation of DNA polymerisation. This process requires 
CDK activity, but also the activity of another kinase - Cdc7/Dbf4 (Jares et al. 
2000; Masai & Arai 2002).  
 
 28 
1.3.2 S phase  
	
S phase refers to the synthesis of the cell’s DNA prior to mitosis. Here, the 
Cyclin E-CDK2 and Cyclin A-CDK2 complexes are the main kinases that drive 
the cell through this DNA replication phase. Appropriate CDK activity ensures 
that accurate DNA replication takes place and also ensures that replication of 
the genome occurs only once per cell cycle. Cyclin E/A-CDK2 activity peaks 
during S phase entry (Fig 1.1), where it has two main functions (Woo & Poon 
2003): Firstly, it participates in the release of the transcription factor E2F from 
RB, to enable transcriptional control of certain genes required for S phase and 
driving S phase entry (Lundberg & Weinberg 1998) (Fig. 1.2). Secondly, it 
phosphorylates components required for the initiation of DNA replication. 
Replication of the genomic DNA during S phase is a well-choreographed, highly 
ordered process involving numerous different proteins (Bell & Dutta 2002; S. 
Tanaka & Araki 2010), and preparation for DNA synthesis begins in G1 phase 
with the licensing of the replication origins which was mentioned earlier. In G1 
phase these origins are licensed, but the helicase is still inactive and initiating 
activation requires the additional binding of multiple cofactors and two kinases 
in order to start unwinding the DNA double helix; Dbf4-dependant kinase (DDK) 
and CDK (Masai et al. 2000; Diffley 2004). The activation of the pre-RC and 
initiation of DNA replication is known as origin firing. Among the cofactors 
required for DNA replication to begin is a protein called Cdc45. Cdc45 interacts 
with the pre-RC and induces loading of Replication Protein A (RPA) and DNA 
polymerase α to initiate origin firing (Zou & Stillman 2000). Phosphorylations by 
Cyclin E/A-CDK2 and DDK are essential for Cdc45 loading onto the origins, 
although it is not clear whether it is Cyclin E or A that is involved. However there 
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is evidence that both can functionally compensate for each other in S phase 
(Woo & Poon 2003; Hochegger et al. 2008). The expression of Cyclin E peaks 
before Cyclin A at the start of S phase (Fig. 1.1), which indicates that Cyclin E-
CDK2 probably dominates in early S phase and are replaced by Cyclin A-CDK2 
complexes later in S phase (H. Zhao et al. 2012). Together, these kinase 
activities regulate the formation of the initiation complex and the initiation of 
replication of licensed origins at the beginning of S phase. 
 
Once DNA replication has begun, bidirectional replication forks are established 
and both DDK and Cyclin E-CDK2 are dispensable for the completion of S 
phase (Bousset & Diffley 1998; S. Tanaka & Araki 2010). This means these 
proteins are in theory only essential for the initiation of DNA replication. The 
inactivation of RB promotes transcription of genes required for subsequent cell 
cycle stages, including Cyclins A and B. Also, the activity of Cyclin A-CDK2 
increases as S phase progresses (Fig. 1.1) (Woo & Poon 2003). The Cyclin A-
CDK2 complexes phosphorylate various targets required for completion and exit 
from S phase, which include targets that promote activation of pre-RC 
complexes and also targets that allow elongation and inhibit the formation of 
new pre-RC complexes (Lundberg & Weinberg 1998; Harbour & Dean 2000; 
Malumbres & Barbacid 2001). 
 
In 1970, cell-fusion experiments carried out by Johnson and Rao indicated the 
presence of a re-replication block (P. N. Rao & R. T. Johnson 1970). The 
results indicated that only G1 cells are competent to carry out DNA replication, 
while cells that have already completed this process, i.e. the G2 cells, were 
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unable to re-replicate their DNA. This re-replication block is key to limiting 
replication to only once per cell cycle, and so preventing genomic instability. It is 
now understood that this occurs due to the two-step nature of the activation of 
DNA replication (Woo & Poon 2003; Remus & Diffley 2009). The first step is 
that CDK activity is relatively low for most of G1 phase, and thus is permissive 
to pre-RC assembly and origin licensing. The second step is, as CDK activity 
increases in S phase, and active Cyclin A-CDK2 complexes predominate, DNA 
replication is initiated, and the pre-RCs are activated. Now the high CDK activity 
inhibits the formation of further pre-RC complexes, thus preventing their 
reformation and CDK activity remains high until the end of mitosis. Different 
thresholds of CDK activity which activate different steps of the cell cycle, is 
therefore critical to ensuring that genomic DNA is replicated exactly once per 
cell cycle and is thus transmitted stably over many cell generations (Hochegger 
et al. 2008). The CDK-mediated inhibition of pre-RC formation occurs in several 
ways. The CDK initiation of origin firing disassembles the pre-RC leaving an 
unlicensed origin and high CDK activity then inhibits the formation of new pre-
RC by several mechanisms: These include the phosphorylation of free Cdc6, 
causing its export from the nucleus and the phosphorylation of the ORC 
complex and Cdt1, leading to their dissociation from the chromatin and/or their 
degradation (V. Q. Nguyen et al. 2001; Takeda & Dutta 2005). 
 
The end of S phase is marked by the completion of the DNA replication. The 
cell then moves into the next phase, G2, in which the cell prepares to equally 
divide its newly doubled complement of chromosomes. 
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1.3.3 G2/M checkpoint  
	
The cell cycle can be arrested at the G2/M transition in response to DNA 
damage and incomplete replication (X. W. Wang et al. 1999; Vairapandi et al. 
2002; Furukawa-Hibi et al. 2002; Kastan & Bartek 2004). Mirroring the 
restriction point in G1 phase, once a cell has progressed past the antephase 
point in G2 phase, then it is committed to undergoing mitosis (Pines & Rieder 
2001). The major effectors of this checkpoint are the ATM/ATR kinases via their 
downstream targets CHEK1 and Chk2 (Abraham 2001; Bartek & Lukas 2003; 
Maréchal & Zou 2013). The major mechanism by which a cell cycle stop is 
introduced by these kinases is the prevention of Cdc25 mediated activation of 
CDK1. Both Cdc25 and Wee1 are direct targets of CHEK1/2 kinases, but there 
is also indirect control via protein stability, localisation and complex formation. It 
remains unclear, if this effects exclusively CDK1, or if CDK2 activity is also 
downregulated by the checkpoint. Both incomplete replication and DNA 
damage signal to the replication checkpoint and recent studies support a model 
whereby ongoing replication intrinsically prevents entry into mitosis via 
constitutive ATR activation (Lemmens et al. 2018; Saldivar et al. 2017). 
1.3.4 G2/M transition  
	
To make sure that cell division produces healthy daughter cells with complete, 
undamaged DNA, the cell has an additional checkpoint before M phase, called 
the G2 checkpoint. At this stage, the cell will check for DNA integrity and 
complete DNA replication. If errors or damage are detected, the cell will pause 
here, and the cell attempts to either complete DNA replication or repair the 
damaged DNA. If the damage is irreparable, the cell may undergo apoptosis.  
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Once DNA replication is complete, cells prepare for sister-chromatid 
segregation and cell division, and enter a cell cycle phase that Walther 
Flemming discovered in the late 19th century and termed mitosis based on the 
Greek word for thread, “mitos” (Rieder 2003). The use of a word for thread 
refers to the appearance of the condensed chromosomes at the onset of 
mitosis, which is one of the many prominent changes the cell undergoes in this 
transition. In fact, almost every cellular compartment is dramatically affected by 
mitotic entry. The nuclear envelope melts into the ER, the Golgi body 
disassembles, the centrosomes separate and start emanating rapidly growing 
and shrinking microtubule fibres, the cell cortex contracts and rounds up, and 
still there are many more examples of mitotic specific changes in the cell 
(Morgan 2007).  
 
These rapid changes are driven by the activation of CDK1, bound to mitotic 
Cyclins (A and/or B). There are three different Cyclin B proteins in mammalian 
cells. Cyclin B3 expression is limited to developing germ cells, and the adult 
testis (T. B. Nguyen et al. 2002). Cyclin B2 is found in cycling adult cells, is non-
essential for mouse development and associates with the Golgi apparatus 
(Jackman et al. 1995; Brandeis et al. 1998). Cyclin B1 is essential for the early 
embryonic cell cycle in developing mice, and is thought to be responsible for 
most of the other actions of CDK1 in the cytoplasm and nucleus during the 
mitotic transition (Brandeis et al. 1998; Strauss et al. 2018). However, siRNA 
depletion of Cyclin B1 in human cells shows a surprising lack of phenotypic 
outcome (Gong & Ferrell 2010), and unpublished work in our lab suggests that 
Cyclin A can compensate most mitotic functions of B-type Cyclins. For simplicity 
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I will call the mitosis promoting activity of CDK1, CDK1/M-Cyclin for the rest of 
this section. 
 
Activation of CDK1 is, thus triggering a critical cellular switch that must be 
extremely tightly regulated. This is achieved at various levels of control. Firstly, 
the expression of M-Cyclins is repressed until required by tight transcriptional 
control via various transcriptional control elements. For example, the promoters 
of Cyclins B1 and B2 (and A1) contain CCAAT-boxes. These DNA sequences 
sequester the transcription factors required for efficient gene expression, for 
example the trimeric nuclear transcription factor Y (NF-Y), (Katula et al. 1997; 
Bolognese et al. 1999; Manni et al. 2001). During mitosis Cyclin B1 can 
continue to be expressed because the chromatin containing the Cyclin B1 gene 
remains in an open formation, and its promoter continues to be bound by NF-Y 
(Sciortino et al. 2001). The transcription factors of Cyclin B – NF-Y, FOXM1 and 
B-MYB, are controlled by CDK activity. This means transcription of Cyclin B is 
only done efficiently once the activity of Cyclin A-CDK2 is sufficiently high 
during S and G2 phases (Bolognese et al. 1999; Fung & Poon 2005). So, the 
Cyclin B levels begin to rise during S phase (Fig. 1.1) and continue to increase 
during G2 phase and remain high in early mitosis. Cyclin B must reach 
sufficiently high a concentration in order to form a high concentration of fully 
active Cyclin-B/CDK1 complexes to drive mitotic entry (Fung & Poon 2005). In 
addition, to become fully active CDK1 requires an activating phosphorylation. 
This is carried about by a Cyclin activating kinase (CAK) on Thr16 in the T-loop 
to create a fully active kinase (Tassan et al. 1994). As mentioned briefly earlier, 
the CAK of CDK1 includes a CDK-Cyclin binding pair: CDK7/Cyclin H (Fesquet 
 34 
et al. 1993; Poon et al. 1993; Fisher & Morgan 1994). The identity of the CAK 
that carries out this phosphorylation varies between organisms, but in humans 
this kinase is composed of a trimeric complex: CDK7, Cyclin H and MAT1 
(ménage à trois 1) (Kaldis et al. 1998). This CAK complex is also responsible 
for the activating phosphorylations of CDK2, CDK4 and CDK6 (Lolli & L. N. 
Johnson 2005; Schachter et al. 2013). 
 
The critical step in M-phase/CDK1 activation is the removal of an inhibitory 
phosphorylation by Cdc25 phosphatases. CDK1 is kept inactive throughout 
interphase by phosphorylations on Threonine (Thr) 14 and Tyrosine (Tyr) 15, 
which are added by the kinases Wee1 (Parker & Piwnica-Worms 1992) and 
Myt1 (Mueller et al. 1995). Switch like activation of this kinase requires a rapid 
removal of these inhibitory phosphates. This is achieved by a positive feedback 
loop. The activated CDK1 can phosphorylate and thus inhibit its own inhibitors 
Myt1 and Wee1, and activate its activator Cdc25 (Perry & Kornbluth 2007). This 
process is included in Figure 1.1. In turn, these enzymes are also controlled 
by DNA damage checkpoints, which delay the onset of mitosis in the 
presence of unreplicated or damaged DNA (Nigg 2001). Finally, spatial 
distribution of various mitotic proteins is also a key feature of mitotic control 
(Álvarez-Fernández et al. 2013). Cyclin B, for example is mainly cytoplasmic 
throughout interphase, but translocates to the nucleus shortly before mitotic 
entry (Toyoshima 1998; Hagting et al. 1999). Other examples of spatial control 
include nuclear Wee1, cortical Myt1, cytoplasmic Cdc25 and others.  The 
precise impact of this spatial control of mitotic entry remains to be determined, 
but preliminary evidence suggest that it plays an important role (Santos et al. 
 35 
2012; Lindqvist et al. 2007; Lindqvist et al. 2009). These factors together 
generate a high concentration of highly active CDK1/M-Cyclin that triggers the 
start of mitosis. 
 
Once active, CDK1/M-Cyclin phosphorylates hundreds of target proteins 
(Dephoure et al. 2008) to cause the transition from interphase to mitosis. These 
CDK1 dependent phosphorylation events orchestrate the dramatic cellular 
rearrangements, including the assembly of a mitotic spindle to enable equal 
separation of the genetic material to two daughter cells.  
 
1.3.5 Spindle Assembly Checkpoint 
 
Once cells have entered mitosis there is one last opportunity for a checkpoint to 
protect the genome, which is called the spindle assembly checkpoint (SAC). 
This checkpoint avoids unequal chromosome segregation by delaying the onset 
of anaphase until all 92 kinetochores of a human cell have attached to 
microtubules extending from opposite spindle poles. This state is called sister 
kinetochore bi-orientation or chromosome bi-orientation (Rieder et al. 1995; T. 
U. Tanaka 2005). Because the separation of the sister chromatids during 
anaphase is an irreversible step, the cycle will not proceed until all the 
chromosomes are firmly attached to at least two spindle fibres from opposite 




1.4  Greatwall kinase and its function in mitotic regulation 
	
Greatwall kinase (GWL), the major subject of this thesis, named in humans as 
microtubule-associated serine/threonine-protein kinase-like (MASTL) (Voets & 
Wolthuis 2010), was first discovered in Drosophila in 2004 (J. Yu et al. 2004). 
The human GWL/MASTL will be referred to as just GWL in this thesis. 
Mutations of this kinase in flies give rise to abnormal mitotic entry with cells 
failing to stabilise a stable mitotic state. This inspired the name of GWL since 
this kinase is required to overcome a barrier to enter mitosis. Further 
biochemical work in Xenopus egg extracts suggested that GWL was working via 
downregulation of PP2A activity to facilitate mitotic entry (Castilho et al. 2009). 
Subsequent work in human cells and conditional knock-out mouse suggested 
that this function of GWL is conserved although the depletion of GWL in 
mammalian cells appears to cause only minor delays in mitotic entry (Álvarez-
Fernández et al. 2013). This discrepancy has remains poorly understood. Since 
the currently major known function of GWL lies in the CDK1 activation switch, 
the context of this signalling cascade at the G2/M transition shall be described 
first. In animal cells, two kinases (Myt1 and Wee1) work together to inhibit 
CDK1 before mitosis via the phosphorylation sites Thr 14 and Tyr 15 on CDK1 
(Welburn et al. 2007). The activities of Myt1 and Wee1 are high for the majority 
of the cell cycle, but then rapidly decrease during mitosis to allow the 
dephosphorylation and thus activation of CDK1 by members of the Cdc25 
phosphatase family (Welburn et al. 2007). These dramatic changes are 
generated in part by the positive feedback loops described previously. Initially, 
the models that described this switch system only focused on the direct 
feedback loops between Wee1, Cdc25 and CDK1. However, this model does 
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not consider the role of the phosphatases that counteract these kinase driven 
feedback systems. Over the past decade it has become apparent that the 
regulation of phosphatases plays a major role in the G2/M transition (Mochida 
et al. 2009; Mochida et al. 2010) and that GWL has a critical function in this 
signalling network (Vigneron et al. 2009). In the first paper to describe GWL, 
mutating the essential Drosophila GWL gene disrupted cell cycle progression 
(J. Yu et al. 2004). The GWL mutant cells took much longer to traverse through 
the period of chromosome condensation from late G2 phase through to nuclear 
envelope breakdown. This means that the chromosomes remain persistently 
under-condensed, and anaphase is delayed due to prolonged activity of the 
spindle checkpoint (J. Yu et al. 2004). To ensure that these phenotypes were 
not artefacts of problems that arose during G1 or S phase and too see what 
happens in vertebrate cells, further experiments were done in Xenopus egg 
extracts, taking advantage of GWL's conservation in vertebrates (Human GWL 
shows 60.5% homology with Xenopus GWL) (J. Yu et al. 2004). Depletion of 
GWL from mitotic Xenopus egg extracts rapidly lowers Maturation Promoting 
Factor (MPF) activity because of the accumulation of inhibitory 
phosphorylations on Cdc2 kinase (the equivalent of human CDK1). Also, GWL 
depletion prevented the Cycling extracts from entering M phase. These results 
suggest that GWL participates in an auto-regulatory loop that generates and 
maintains sufficiently high MPF activity levels to support mitosis.  
 
The inactivation of Cyclin B-CDK1 was prevented in mitotic Xenopus egg 
extracts by the immunodepletion of the inhibitory kinases Wee1 and Myt1, 
and the subsequent immunodepletion of GWL from these extracts still 
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promoted mitotic exit (Vigneron et al. 2009). This exit from mitosis was 
accompanied by a dephosphorylation of most of the substrates of Cyclin B-
CDK1 despite the high activity of this kinase. However, this massive 
dephosphorylation was not observed when the mitotic egg extracts were 
submitted to a co-depletion of GWL and PP2A. These were the first data 
suggesting a role of GWL in the inhibition of PP2A (Vigneron et al. 2009). 
Soon after, multiple research groups also established that GWL maintains the 
mitotic state not by regulating the Cyclin B–Cdc2 activation loop, but by 
regulating the phosphatase PP2A-B55 (Castilho et al. 2009; Mochida et al. 
2009). Later, two groups in particular established the elusive substrates of GWL 
that mediate this phosphatase inhibition as α-Endosulfine (ENSA) and cyclic 
adenosine monophosphate (cAMP)-regulated phospho-protein 19 (ARPP19) 
(Mochida et al. 2010; Gharbi-Ayachi et al. 2010). The Mochida et al. (2010) 
study identified the GWL substrate, ENSA, from interphase Xenopus egg 
extracts, while the Gharbi-Ayachi et al. (2010) study identified ARPP19 using 
biochemical fractionation of Cytostatic factor (CSF) Xenopus egg extracts and 
in vitro Greatwall kinase assays. Whether ARPP19 and ENSA have distinct and 
separate roles in this particular pathway remains to be established (Lorca & 
Castro 2012) but it is clear from the data from several groups that both these 
proteins can act downstream of Greatwall to inhibit PP2A to allow correct mitotic 
entry and progression. This allows the CDK1 activity to predominate and drive 
entry into mitosis. 
 
Further studies in Xenopus egg extracts found that GWL can promote recovery 
from DNA damage and that GWL is directly inhibited by the DNA damage 
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response (DDR) (Peng et al. 2010). Immuno-depletion of GWL increased the 
DDR, whereas addition of wild-type, but not kinase-dead GWL, inhibited the 
DDR (Peng et al. 2010). The removal of damaged DNA from the egg extracts 
caused recovery from checkpoint arrest and mitotic entry, which was impaired 
by GWL depletion and enhanced by GWL overexpression (Peng et al. 2010). A 
later Xenopus study found that GWL is able to promote checkpoint recovery 
independently of CDK1 or Plx1 (the Xenopus homolog of polo-like kinase 1) 
(Peng et al. 2011).  A direct interaction between GWL and Plx1 was found in 
which Plx1 phosphorylates GWL and that this GWL interaction and 
phosphorylation by Plx1 appears elevated during checkpoint recovery(Peng et 
al. 2011). So overall, synergy between Plx1 and GWL are required for 
reactivation of these kinases from the G2/M DNA damage checkpoint and 
efficient checkpoint recovery (Peng et al. 2011). More work has now been 
carried out to try and understand the exact role of GWL in mammalian and 
human cells. In agreement with the results described above, in human cells 
GWL also indirectly inhibits PP2A-B55 via phosphorylation of ENSA and 
ARPP19 (Cundell et al. 2013; Álvarez-Fernández et al. 2013).  
 
The human GWL protein is stably expressed throughout the cell cycle but is 
phosphorylated and most active during mitosis (Dephoure et al. 2008; Voets & 
Wolthuis 2010; Olsen et al. 2010). Depletion of GWL expression in human cells 
causes problems in mitotic progression including defects in chromosome 
condensation and separation (Burgess et al. 2010; Álvarez-Fernández et al. 
2013). It has been found that depleting human cell lines of GWL using siRNA 
caused a delay in mitotic entry, chromosome alignment defects and metaphase 
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delay (Burgess et al. 2010) and aberrant chromosome segregation resulting in 
polyploidy. In addition, depletion of GWL by siRNA in the human cell lines RPE, 
U2OS and HeLa delays the G2/M transition, and is associated with an extended 
mitosis period, failures in sister chromatid segregation and mitotic cell death 
(Voets & Wolthuis, 2010). The phenotypes of GWL overexpression or 
depletion in model organisms and common experimental human cell lines are 
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2015) 
 
Table 1.1 A summary of known phenotypes of GWL depletion and 
overexpression in some model organisms and human cell lines. 
 
In summary, the main mitotic role of GWL in human cells is to inhibit the 
phosphatase PP2A–B55 that permits the maintenance of the phosphates on 
mitotic substrates of Cyclin B-CDK1. This is important because this enormous 
phosphorylation event is essential to promote the complex, dynamic events of 
mitosis. A visual depiction of the consensus of GWL signalling during mitotic 
entry can be seen in Figure 1.3.  
 
1.5 PP1 and PP2A as regulators of mitosis 
	
The role of the phosphatases that are in opposition the kinase signalling events 
is starting to be more appreciated as a crucial aspect of the control of mitotic 
entry and exit (Bollen et al. 2009; De Wulf et al. 2009). Studies are now 
revealing that the timely ordering of mitotic events, in fact, appears to be a 
result of a delicate interplay between both the kinases and their counteracting 
phosphatases (Domingo-Sananes et al. 2011). Previously, phosphatases were 
given less appreciation because they were thought of as indiscriminate and 
broad acting in their dephosphorylation. Indeed, phosphatases are broad-
acting in vivo. For instance, PP1 controls processes as diverse as glycogen 
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metabolism, cell polarity, DNA damage, transcription, and cell cycle progression 
(De Wulf et al. 2009). This suggests that the roles of phosphatases within 
mitosis are hidden by secondary phenotypes. In addition, the gene numbers 
encoding kinase and phosphatase activities are disproportionate. 
 
Approximately 500 human genes have been estimated to encode protein 
kinases, whilst only about 40 appear to code for serine/threonine phosphatases 
(which make up 98% of phosphorylations in mammalian cells) (Manning et al. 
2002; Moorhead et al. 2007; Wlodarchak & Xing 2016). The consensus is now 
changing and phosphatases are seen as highly specific inhibitors of precise 
signalling pathways and feedback loops that are critical for the control of mitotic 
events (De Wulf et al. 2009; Domingo-Sananes et al. 2011). For example, the 
down-regulation of CDK1 is not sufficient for mitotic exit in human cells. Human 
cells with reduced CDK1 activity do not progress past metaphase when the 
protein phosphatases PP1 and PP2A are selectively inhibited (L. Zhu & 
Skoultchi 2001). Also, it is well known in biology that gene number does not 
necessarily reflect protein number or complexity, as some of the 
serine/threonine phosphatases form a large number of diverse oligomeric 
complexes. In particular, PP2A forms ~100 heterotrimeric holoenzymes and 
protein phosphatase 1 (PP1) forms ~400 heterodimeric holoenzymes meaning 
that these are not single enzymes but rather a family of enzymes (Ruvolo 2016; 
Wlodarchak & Xing 2016). PP2A is a trimeric enzyme with common catalytic (C) 
and A (‘scaffolding’) subunits but variable B (regulatory) subunits, and PP2A 
isoforms are identified by the B regulatory subunit they contain, which also 
determines the substrate specificity and cellular localisation of the resulting 
PP2A isoform (Ruvolo 2016).  
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The large diversity of holoenzyme structure that can be achieved means that 
PP2A has been suggested or confirmed to dephosphorylate over 300 
substrates, most of which are involved in cell cycle regulation (Wlodarchak & 
Xing 2016). PP2A has been implicated in preventing of premature separation of 
chromosomes in anaphase. PP2A, in complex with the regulatory B56 subunit, 
is recruited to the centromeres by the Shugoshin protein and keeps cohesion 
subunits in an unphosphorylated state, counteracting Plk1 phosphorylation 
(Kitajima et al. 2006; Tang et al. 2006; Barr et al. 2011). Also PP2A, in complex 
with is regulatory B55α subunit, has been implicated in Golgi reassembly after 
mitotic exit (Schmitz et al. 2010). The role of PP2A which is of most importance 
to this thesis is that is has been discovered to be an important part of the 
signalling network required to allow timely mitotic progression, specifically 
PP2A-B55 (Mochida et al. 2009; Castilho et al. 2009; Vigneron et al. 2009; 
Lorca & Castro 2012). Also, the dephosphorylation and thus the activation of 
the anaphase spindle protein PRC1 is controlled by a PP2A-B55 isoform 
(Cundell et al. 2013). 
 
In addition, B55 has been implicated in reassembly of the Golgi apparatus and 
nuclear envelope during mitotic exit (Schmitz et al. 2010). As mentioned 
previously, PP2A-B55 is inhibited in mitosis by ENSA and ARPP19 (Gharbi-
Ayachi et al. 2010; Mochida et al. 2010). Together, these components form the 
BEG (B55–ENSA–Greatwall) pathway controlling mitotic exit (Cundell et al. 
2013). Because Cyclin B-CDK1 activates GWL, the PP2A-B55 inhibition is 
maintained until Cyclin B is degraded (Castilho et al. 2009; Gharbi-Ayachi et al. 
2010; Mochida et al. 2010). 
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Once all chromosomes have aligned and are under tension on the metaphase 
spindle, the anaphase-promoting complex triggers destruction of Cyclin B and 
the separase inhibitor securin. This leaves an interesting problem of how PP2A-
B55 is reactivated and Greatwall kinase is inhibited during mitotic exit. The 
current models of the phosphatase regulation during the metaphase anaphase 
transition suggest that PP1 first inactivates Greatwall (Heim et al. 2015) by 
dephosphorylating a C-terminal site that is thought to be essential for kinase 
activity. Once Greatwall is inactive, PP2A-B55 itself dephosphorylates its 
inhibitor ENSA/ARPP19. Removal of the ENSA–Greatwall inhibitory system 
results in constitutive B55 activity, causing mitotic catastrophe and unequal 
chromosome segregation because of precocious central spindle formation and 













Figure 1.3 The Greatwall kinase pathway A diagram of the current consen-
sus of GWL signalling during mitotic entry in mammalian cells. GWL is activat-
ed in late G2 phase and phosphorylates its targets, ENSA and Arpp19 (for sim-
plicity, just ENSA is shown on this schematic), which in turn bind to and inhibit 
the PP2A-B55 phosphatase. This prevents PP2A-B55 from prematurely 
dephosphorylating substrates of CDK1. This allows mitotic phosphorylations 
to accumulate and drive cells through mitosis. It is possible that PP1 phos-




























1.6 The cell cycle and cancer 
	
Cells have evolved to cope with both metabolic and external sources of DNA-
damaging agents through the development of elegant DNA repair 
mechanisms. This is called the DNA damage response (DDR), which is a 
collective term for the huge network of an estimated 450 proteins (Pearl et al. 
2015) that seek to detect and repair DNA damage. This also includes events 
that lead to cell-cycle arrest, regulation of DNA replication, and the repair or 
bypass of DNA damage. In the event of sufficient DNA repair not being possible 
or suboptimal, the DDR can also impact on downstream cell fate decisions, 
such as cell death or senescence (D'Adda Di Fagagna et al. 2003; Kang et al. 
2015; M. J. O’Connor 2015). Such mechanisms are vital for life, because DNA 
is under constant attack by agents that can directly damage the nucleotide 
bases or the phosphodiester backbone of the DNA molecule. For example, 
free oxygen radicals, arise as a consequence of normal cellular metabolism 
or can be formed when the organism is exposed to ionizing radiation in the 
environment (Kastan & Bartek 2004). In metazoans, it could be said that the 
cell cycle checkpoints and DNA repair mechanisms exist as a method of 
protection against cancer. 
 
However, deregulating the cell cycle is a primary agenda for the emerging 
cancer cell, as this tightly regulated process controls cell growth. Multiple 
checkpoints are in place that assesses a cell’s extracellular growth signals, its 
size, and DNA integrity at all times. If a cancer cell is to grow to become a 
clinically relevant tumour, cancer cells have to overcome the cell cycle control 
machinery. Cancer cells also display many additional differences to normal 
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cells as well as unscheduled proliferation – such as genomic instability 
(increased DNA mutations and chromosomal aberrations), chromosomal 
instability (changes in chromosome number), loss of differentiation and 
increased invasiveness (Hanahan & Weinberg 2011). Markers of DNA 
damage can often be a phenotype of genetically unstable cancer cells. For 
example, certain markers of double strand breaks (DSBs), such as nuclear 
γH2AX foci (a histone phosphorylation event that occurs on chromatin 
surrounding a DSB), are markedly elevated in some precancerous lesions 
(Lord & Ashworth 2012). Taken together, these alterations of normal cells, 
cause both proliferative advantages and increased susceptibility to the 
accumulation of further mutations or genetic misregulation that contribute to 
tumour progression and acquisition of more oncogenic phenotypes. The three 
cell cycle defects that are essential for the growth of cancer cells - 
unscheduled proliferation, genomic instability and chromosomal instability, 
are mediated, directly or indirectly, by the misregulation of Cyclin-dependent 
kinases (Malumbres & Barbacid 2005). 
 
As mentioned earlier, CDK activity is regulated by two groups of inhibitors: 
the INK4 family, and the Cip and Kip family, composed of p21, p27 and p57 
(Sherr & Roberts 1999; Malumbres & Barbacid 2009). These CKI proteins are 
able to block the proliferation of adult stem cells in various tissue types 
(Malumbres & Barbacid 2009). Also, knock-in mice expressing a mutant p27 
protein are unable to bind Cyclin-CDK complexes, display increased stem 
and progenitor cell populations and a range of tumour susceptibilities (Besson 
et al. 2007). The key regulators of G1 phase progression are perturbed in 
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most human cancers. For example, deregulation of CDK4 and CDK6 
activities and their substrates (mostly RB) have been implicated in a wide 
variety of tumours (Ortega et al. 2002; Malumbres & Barbacid 2005). RB 
function can be lost through mutation of the RB1 gene, with tumours such as 
retinoblastomas, osteosarcomas and small-cell lung carcinomas displaying 
particularly high occurrences of RB1 mutation (Chinnam & Goodrich 2011; Di 
Fiore et al. 2013). RB loss of function can also occur after a cell is infected 
with Human Papilloma Virus (HPV), as the viral oncoprotein E7 can bind to 
RB and prevent interaction with E2F. This prevents RB from inhibiting cell 
cycle progression, and HPV infection plays a key role in the development of 
the vast majority of cervical carcinomas (Yim & Park 2005; Munger & D. L. 
Jones 2015). 
 
Another strategy that cancer cells employ to deregulate cell cycle control is 
through the MYC transcription factor. When MYC is deregulated, it is an 
oncoprotein. Elevated levels of Myc protein are found in many different types of 
human cancer and may be deregulated in as many as fifty per cent or more of 
all tumours (Kalkat et al. 2017; Chen et al. 2018). MYC belongs to a family of 
basic helix-loop-helix (bHLH) transcription factors that act as heterodimers to 
influence the transcription of a large number of target genes that possess E-box 
sequences (S. Jones 2004). The Mad-Max complexes repress transcription, 
whereas Myc-Max complexes act to promote transcription, and the protein 
products of many of these target genes influence the cell cycle. For example, 
the Myc-Max heterodimer can induce expression of the growth-promoting 
proteins E2F, Cyclin D and CDK4 (Obaya et al. 2002; Liao et al. 2007). Also, 
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Myc-Max can cause expression of Cul1, which is responsible for degrading the 
CDK inhibitor p27Kip1 (Grandori et al. 2000). Another binding partner of Myc - 
Miz1 - can repress expression of the CDK inhibitors p15INK4b, p21Cip1 and 
p27Kip1 (Wiese et al. 2013). Overall there are several ways in which an excess 
of the Myc oncoprotein can act to deregulate the cell cycle machinery, and so 
facilitate pre-cancerous or cancerous cells through their growth and division 
cycles.  
 
In general, basic regulators of G1 progression are altered in most human 
cancers. Genetic alterations usually affect CDK4 and CDK6, their positive 
(mainly cyclin D1) and/or negative (INK4A and INK4B) regulators and their 
substrates (mainly RB). Even if the Rb protein itself is not mutated, alterations 
to other gene products are common events in tumourigenesis. Repression of 
the RB gene by methylation at its promoter (Stirzaker et al. 1997; Feinberg & 
Tycko 2004), inactivation by viral oncoproteins as mentioned previously (Yim & 
Park 2005; Munger & D. L. Jones 2015), elevated levels of Cyclin D1 (Arnold & 
Papanikolaou 2005), and suppression of CDK inhibitor activity (Malumbres & 
Barbacid 2001). The different types of G1 regulator mutations and in what 
tumours they are found in are extensively classified in this review (Malumbres & 
Barbacid 2001). 
 
There have been analyses of the genes deregulated in chromosomally 
unstable tumours which have found that misregulation of genes involved in 
G2 and M phases is also common (Perez de Castro et al. 2006; Carter et al. 
2006). These genetic signatures include overexpression of CDK1 and some 
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of its regulators such as Cyclin B1 and B2, as well as components of the 
centrosome and chromosome segregation machinery, such as NEK2, Aurora 
kinase A, Aurora kinase B, Cdc20, CENPF (Centromere protein F), Separase, 
and Securin (Carter et al. 2006). 
 
Since CDKs, other cell cycle kinases, and their binding partners and 
substrates are frequently hijacked in the context of cancerous cells; this 
raises the question of how to devise therapeutic strategies based on 
knowledge of the cell cycle machinery and how certain cancer cells 
manipulate it. Though caution must be taken, as cell cycle control is so 
broadly important for multi-cellular life and there are numerous highly 
proliferative tissues in the body; therapeutics designed to target cell cycle 
control should aim to be as selective for tumour cells as possible. 
 
However, despite this challenge, cancer therapeutics that target the cell cycle 
are already in clinical use. One group of drugs targets the cytoskeleton, with the 
aim of interfering with chromosome separation and mitosis in cancerous cells to 
limit their proliferation. For example, Paclitaxel (or Taxol) stabilises the 
microtubule polymer and inhibits its disassembly. This means Paclitaxel-treated 
cells are unable to form the metaphase spindle configuration that is required to 
pass the SAC (Bharadwaj & H. Yu 2004; Brito et al. 2008). In contrast, other 
cytoskeleton-targeting chemotherapy drugs such as Demecolcine and 
Vinblastine can work either by depolymerising the microtubules or by preventing 
their assembly, depending on the concentration used (Jordan & Wilson 2004). 
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Additionally, recent research has shown therapeutic potential kinases that 
facilitate DNA replication and repair. For example, Ataxia telangiectasia mutated 
kinase (ATM), Ataxia telangiectasia and Rad3-related kinase (ATR), and 
Checkpoint 1 and 2 kinases (CHEK1 and CHEK2). CHEK1, CHEK2, ATM and 
ATR have roles in arresting the cell cycle in the event of DNA damage (J.-H. 
Lee & Paull 2007; E. J. Brown & Baltimore 2003). The ATM–CHEK2 pathway is 
activated in response to ionizing radiation treatment and agents that cause 
double-strand DNA breaks. ATM phosphorylates and activates CHEK2, which 
in turn phosphorylates Cdc25c at Serine 216. This promotes binding of the 
members of the 14-3-3 protein family, nuclear export, and cytoplasmic 
sequestration of Cdc25c. This suppression of the Cdc25c phosphatase activity 
and its nuclear exclusion prevents it from activating Cyclin B-CDK1, and so 
preventing mitotic entry (Boutros et al. 2007; Matheson et al. 2016). The ATR–
CHEK1 pathway is activated by regions of single stranded (ss)DNA that have 
been complexed with RPA (Smith et al. 2010; Bartek & Lukas 2003). Single 
stranded breaks can arise from a broad range of genotoxic stresses. In 
response to ssDNA damage, ATR phosphorylates and activates CHEK1, which 
then phosphorylates Wee1 and Cdc25c, thereby simultaneously activating 
Wee1 kinase activity and inactivating Cdc25c phosphatase activity. This allows 
Wee1 to phosphorylate the Tyrosine 15 residue, which inactivates Cyclin B-
CDK1, causing cell-cycle arrest in G2 phase (Matheson et al. 2016; Do et al. 
2013; N. Johnson et al. 2009; Jazayeri et al. 2005). 
 
Therefore these DDR pathways act in a tumour suppressive manner, so whilst it 
is not surprising that mutations and/or deletions of ATM and Chk2 are often 
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found in a range of human cancers (Manic et al. 2015; Antoni et al. 2007), it is 
interesting to note that the opposite seems to be true in the case of the ATR-
CHEK1 axis (Manic et al. 2015). The incidence of ATR or CHEK1 gene loss or 
mutations in human cancers is generally quite low, but with some notable 
exceptions. For example, CHEK1 has found to be frequently overexpressed in 
Triple Negative breast cancers (TNBC) (Verlinden et al. 2007; Albiges et al. 
2014). Cancer cells with defects in the G1/S checkpoint are thought to rely more 
on the ATR-CHEK1 pathway, so even though these cells are upregulating a 
DDR pathway, this means they are more vulnerable to its inhibition (Garrett & 
Collins 2011; Fokas et al. 2014; McNeely et al. 2014). Interestingly, inhibitors of 
ATR and CHEK1, are the only two classes of compounds from the proteins 
discussed in this paragraph that have so far entered clinics (Manic et al. 2015). 
 
The inhibitory kinase Wee1 that inactivates CDK1 in response to various types 
of DNA damage, as explained above, is also a subject of clinical cancer 
research. Wee1 is expressed in high amounts in a range of cancers, including 
breast, liver, cervical and lung cancers (Masaki et al. 2003; Iorns et al. 2009). 
The rationale of Wee1 as a therapeutic target is that cancer cells that 
overexpress Wee1 may be more reliant on an intact G2/M checkpoint for 
survival and mitosis. Therefore, inhibition of Wee1 activity may sensitise 
cancers dependent on a functional G2/M checkpoint to DNA-damaging drugs. 
Since Wee1 inhibition promotes mitosis, this propagates further genomic 
instability in cancer cells by forcing the cell through successive replication 
cycles, with the aim to induce apoptosis from mitotic catastrophe. Therefore, the 
inhibition of Wee1 could increase the efficacy of existing conventional DNA-
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damaging therapies (Matheson et al. 2016; Do et al. 2013). There is a Wee1 
inhibitor, AZD1775, which has progressed into clinical trials in combination with 
DNA-damaging therapies (Matheson et al. 2016; Do et al. 2015; Schellens et al. 
2011). 
 
When it was discovered over 30 years ago that CDK holoenzymes are the key 
drivers of cell cycle specific events (M. G. Lee & Nurse 1987), CDK inhibitors 
were developed as potential cancer therapeutics. The first-generation CDK 
inhibitors were rather unspecific in their mechanism of action and so are also 
referred to as ‘pan-CDK inhibitors’, one example in particular being flavopiridol 
(Sedlacek et al. 1996) which carried high expectations and featured in over 60 
clinical trials, but showed low efficacy in Phase II clinical trials (Asghar et al. 
2015). The next generation of CDK inhibitors sought to increase specificity for 
CDK1 and CDK2, but only a few molecules progressed past Phase I clinical 
trails (Misra et al. 2004; Payton et al. 2006; Parry et al. 2010; DePinto et al. 
2006). The reasons why such pan-CDK inhibitors were unsuccessful can be 
attributed to: lack of understanding of the mechanism of action, no knowledge 
of biomarkers to find subpopulations of patients who could benefit most from 
the treatment, and finally the broad action of these drugs meant the therapeutic 
window was small, and so very little discrimination between normal and 
cancerous cells (Asghar et al. 2015). The described disadvantages to these 
pan-CDK inhibitors means that improved understanding of which CDK 
holoenzymes are active and when in vivo as well as greater CDK specificity is 
needed if CDK inhibitors are to be successful as cancer therapeutics.  
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CDK4/6 inhibitors have emerged as appealing therapeutic target. The 
mechanism of action is well understood, as the primary mode of action would 
be suppression of RB phosphorylation and so inhibiting proliferation by 
enforcing cell cycle arrest in G1 phase. However, depending on the cell type 
and the transforming event, some RB-positive cells undergo quiescence and 
others undergo senescence when treated with CDK4/6 inhibitors so more 
needs to be understood about the circumstances that bring about these two 
different non-proliferative states (Baughn et al. 2006; Kovatcheva et al. 2015; 
Choi et al. 2012; Michaud et al. 2010). Also, patients could be stratified for 
tumours that have deregulated components of this pathway, with the 
exception of RB-negative tumours (Klein et al. 2018; Pernas et al. 2018; 
Asghar et al. 2015). There is evidence the Cyclin D-CDK4/6 axis is 
hyperactive in a range of breast cancers which makes targeting CDK4/6 a 
promising therapeutic strategy (Arnold & Papanikolaou 2005; Q. Yu et al. 2001; 
Q. Yu et al. 2006). The first CDK4/6 inhibitor to enter clinical use was 
Palbociclib (Finn et al. 2016) followed by Ribociclib and Abemaciclib (Gelbert 
et al. 2014; Tripathy et al. 2017). More about CDK4/6 inhibition in cancer 
therapy is described in Section 1.8.  
 
1.7 Greatwall Kinase in triple negative breast cancer 
	
Approximately 12 to 17% of female breast cancer patients (Foulkes et al. 2010) 
and 6% of male breast cancer patients (Plasilova et al. 2016) are diagnosed 
with Triple-negative breast cancer (TNBC). TNBC is distinctive by its lack of 
expression of common breast cancer cell growth drivers, as it is defined as a 
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breast tumour that lacks expression of the oestrogen receptor (ER), 
progesterone receptor (PR) and the Human epidermal growth factor receptor 2 
(HER2) (Foulkes et al. 2010; Stockmans et al. 2008).  
 
So not only does TNBC represent a heterogeneous group of tumours, but also 
TNBC lacks the targets required for treatment with hormone therapies or drugs 
that target the HER2 receptor, therefore treatment options for TNBC are 
currently limited to chemotherapy and surgery. This fact combined with the 
aggressive nature of TNBC tumours mean that prognosis is often worse for 
TNBC than other breast cancer types, (Gadi & Davidson 2017; Stockmans et al. 
2008; P. Sharma 2016). TNBCs are associated with a 4-fold increased risk of 
metastases and a significantly shorter overall survival (Marmé & Schneeweiss 
2015). 
 
Current research efforts are focused on identifying targets and agents that 
could bring benefit specifically to the TNBC subtype. In addition, optimising 
existing treatments for TNBC is ongoing as knowledge grows regarding use of 
current chemotherapy agents and regimes (Liedtke et al. 2008). For example, 
some patients with primary TNBC tumours that express a high proportion of 
basal-like genes have a high likelihood of response to chemotherapy, but if the 
tumour is not chemo-sensitive, then they have a worse outlook given the 
reliance on chemotherapy (Marmé & Schneeweiss 2015; Schneider et al. 
2008). Improved understanding in what drives TNBC cell growth and 
identification of different molecular subtypes of TNBC may aid in further 
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tailoring treatment for this type of breast cancer (P. Sharma 2016; Schneider et 
al. 2008). 
 
Studies have shown that GWL is often overexpressed in a range of human 
cancers, including breast cancer (L. Wang et al. 2014) (Rogers et al. 2018). It 
has also been shown that GWL protein expression levels can vary dramatically 
across different Squamous Cell Carcinoma (SCC) cell lines (L. Wang et al. 
2014). GWL overexpression also encouraged transforming behaviour in 
immortalised, non-transformed cells and can increase in vitro and in vivo tumour 
cell proliferation (Vera et al. 2015). Therefore it may be that GWL is not required 
in large amounts to maintain CDK1 activity during a normal, unperturbed cell 
cycle, but instead is required more urgently in order to reach more robust levels 
of CDK1 activation in certain situations (Álvarez-Fernández et al. 2013). For 
example, during checkpoint recovery following cell cycle arrest after DNA 
damage events (Peng et al. 2010).  
 
A caveat with the current body of knowledge about GWL is that most of the 
research has been done in cancer cell lines. Therefore, it is largely unknown 
what effects GWL inactivation or depletion has on the health and survival of 
non-transformed cell lines. For example one study could not detect GWL mRNA 
in a range of human tissues including the brain, thalamus, pituitary gland, heart, 
spinal cord, stomach, lung, testis, ovary and kidney (H. J. Johnson et al. 2009), 
which is contradictory to the theory that GWL is a key player in mitotic entry 
(Voets & Wolthuis 2010). It is possible that the human GWL protein is more 
important for genetically unstable and constantly dividing cancer cells, which 
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makes GWL an attractive target in cancer therapy research because there is a 
possibility that its inhibition may not be too harmful to non-cancerous 
proliferating cells in the body. It thus could be possible that cancer cells, being 
more genetically damaged and unstable than normal cells, are more reliant on 
GWL. 
 
1.8 CDK4/6 inhibition in triple negative breast cancer 
	
Traditionally, CDK4/6 inhibition has been viewed as a poor therapeutic target 
for TNBC, because these tumours often show loss of the RB1 gene or RB 
function (Herschkowitz et al. 2008). CDK4/6 inhibition has shown to be a 
promising monotherapy agent in hormone sensitive breast cancers (DeMichele 
et al. 2015; Finn et al. 2015; N. C. Turner et al. 2015; Hortobagyi et al. 2016; 
Finn et al. 2016), and the CDK4/6 inhibitors Palbociclib (IBRANCE®) and 
Ribociclib (Kisqali®) are in clinical use for breast cancer patients in the UK and 
US (Iacobucci 2017; Kmietowicz 2017; Finn et al. 2016; Hortobagyi et al. 2016). 
A third CDK/6 inhibitor, Abemaciclib, is under investigation in clinical trials and 
has been recently approved by the US Food and Drug Administration (FDA) 
(Polk et al. 2017; Patnaik et al. 2016). However, as previously mentioned, 
TNBC is a molecularly heterogeneous cancer known for its genomic instability, 
high expression of cyclin E1 (Network et al. 2012) and has shown resistance to 
single-agent CDK4/6 inhibition (DeMichele et al. 2015; Finn et al. 2009). 
However, because of the urgent need to find targets that could be beneficial to 
TNBC patients, it would be beneficial identify biomarkers that could identify 
situations in which it would be effective to inhibit CDK4/6 in certain TNBC 
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tumours. It has been found that some types of TNBC cell are resistant to 
CDK4/6 inhibition (Asghar et al. 2017). However this study found some 
exceptions, for example CDK4/6 inhibition was effective in the luminal androgen 
receptor (LAR) subtype of TNBC in vitro and in vivo (Asghar et al. 2017). Also, if 
a certain type of cancer cell is resistant to a particular monotherapy, there could 
be novel combinations of therapies that are highly effective against TNBC. For 
example, the crosstalk between the CDK4/6 and the PI3K–AKT–mTOR 
pathways, including many negative feedback loops, has yielded strong rationale 
for combining inhibitors through these pathways to inhibit tumour growth, and 
this strategy has been effective in ER-positive and HER2-postive breast cancer 
cells which were previously resistant to CDK4/6 inhibition alone (Vora et al. 
2014; Goel et al. 2016; Herrera-Abreu et al. 2016). A synergistic effect between 
PI3K and CDK4/6 has also been observed in TNBC cells. In a panel of TNBC 
cells, both the combination of Palbociclib with Taselisib (in PIK3CA-mutant 
TNBC cells) or of Ribociclib with Alpelisib resulted in enhanced cell cycle arrest 
and apoptosis, than either drug alone (Asghar et al. 2017; Teo et al. 2017). In 
the study by Asghar and colleagues, the synergy between PI3K and CDK4/6 
inhibitors sensitised some TNBC cell types to CDK4/6 inhibitor sensitivity 
(Asghar et al. 2017). 
 
Such research means that there is a strong pre-clinical rationale for researching 
CDK4/6 inhibitors in different molecular subtypes of breast cancer, including 
TNBC, and for testing new combinations of treatments alongside CDK4/6 
inhibitors. 
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1.9 Thesis aims 
	
At the beginning of this project I was planning to focus my studies on how GWL 
contributes to tumourigenesis, and perhaps try and establish a biomarker that 
predicts the dependency of cancer cells on elevated GWL expression. As time 
progressed, other research groups studying GWL in the context of cancer 
published results that, whilst supportive of the work we have done in this thesis, 
meant that our own strategy had to be flexible to avoid too much repetition. The 
work in this thesis addresses two themes of GWL biology in TNBC cells: The 
first chapter establishes the GWL depletion phenotypes in a panel of breast 
cells, and the second theme, which forms multiple chapters, explores a key 
result from a siRNA and drug screen, which found a novel synthetic lethality 
between GWL and CDK4/6. After validating this screen hit experimentally, we 
decided to explore the mechanism of this relationship because not only is it 
novel and exciting from a basic biology perspective, but also combined with the 
fact that there are successful CDK4/6 inhibitors in clinical use, so this 
information could bear fruit for future translational work. 
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Chapter 2. Materials & Methods 
2.1 Materials 
 
2.1.1 Human cell lines and cell culture 
	
The cell lines used in this project are listed below in Table 2.1. Before 
experiments began, the cell lines were tested for mycoplasma contamination 
and their identities authenticated using a short tandem repeat (STR) DNA 
profiling service. Cell lines were tested for mycoplasma contamination regularly 
throughout the project. 
 
Cell line  Origin 
MDA-MB-231 
Breast (adenocarcinoma; Triple 
Negative; Basal B) 
MDA-MB-436 
Breast (invasive ductal carcinoma; Triple 
Negative; Basal B) 
MDA-MB-468 
Breast (adenocarcinoma; Triple 
Negative; Basal A) 
HS578T 
Breast (carcinosarcoma; Triple Negative; 
Basal B) 
MCF10a 
Breast (immortalised fibrocystic 
epithelia) 
 
Table 2.1: Cell lines used in project Information about the phenotype of the 
cell lines was obtained from the American Type Culture Collection and a study 
by Chavez et al. (Chavez et al. 2010). 
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All cancer cell lines were cultured in Dulbecco's modified Eagle Medium 
(DMEM) (Life Technologies) supplemented with 10% Tetracycline-free FBS 
(PAN Biotech). The immortalised breast epithelial cell line MCF10a was 
cultured in DMEM/F12 (Life Technologies) supplemented with 10% 
Tetracycline-free FBS (PAN Biotech), 20ng/mL EGF (Peprotech), 0.5mg/mL 
Hydrocortisone (Sigma), 100ng/mL Cholera Toxin (Sigma) and 10 µg/mL Insulin 
(Sigma). 
 
The media of all cells was supplemented with 100U/mL penicillin and 0.1mg/mL 
streptomycin (Life Technologies). All cells were cultured in a 37°C, 5% CO2 
incubator.  
 




• Doxycycline (Sigma); stored in powder form at 4°C protected from light. 
Aliquots dissolved in water, stored at -20°C protected from light. 
• CDK4/6 inhibitor Lee011/Ribociclib (Selleckchem). Aliquots dissolved in 
DMSO, stored at -20°C protected from light. 
• CDK4/6 inhibitor Palbociclib (Selleckchem). Aliquots dissolved in DMSO, 






4x Sample Buffer for Immunoblotting 
10 mL     Working concentration 1x  
2.0 mL 1M Tris-HCl, pH 6.8 50 mM 
0.8 g SDS    2% 
4.0 mL 100% glycerol  10% 
0.4 mL 14.7 M β-mercaptoethanol 1% 
1.0 mL 0.5 M EDTA   12.5 mM 
8.0 mg bromophenol blue  0.02% 
2.6 mL dH2O 
 
10x SDS running buffer for SDS-PAGE 
Per litre dH2O: 
121.1 g Tris Base 
576.5 g Glycine 
40 g SDS 
Diluted to 1x with dH2O prior to use 
 
Immunoblotting buffers 
Anode 1: 300 mM Tris, 20% methanol, pH 10.4 
Per litre: 
200 mL methanol 
36.3 g TRIZMA base (Fisher) 
Made up to 1 L with dH2O  
Anode 2: 25 mM Tris, 20% methanol, pH 10.4 
 67 
Per litre: 
200 mL methanol 
3.02 g TRIZMA base (Fisher) 
Made up to 1 L with dH2O  
Cathode: 25 mM Tris, 40 mM 6-aminohexanoic acid, 20% methanol, pH 9.6 
Per litre: 
200 mL methanol 
3.02 g TRIZMA base (Fisher) 
5.24 g 6-aminohexanoic acid (Sigma) 
Made up to 1 L with dH2O 
 
2.1.4 Primary antibodies 
	
The names, sources and the dilutions of the primary antibodies used are listed 
in Table 2.2. Primary antibodies stored at -20°C. 
 
 







Sigma (HPA054273) Rabbit 1:500 (IB); 
1:200 (IF) 
α-Tubulin 




Millipore (05-636) Mouse 1:1000 (IF) 
α-Endosulfine 
(ENSA) 
Abcam (ab125873) Rabbit 1:1000 (IB) 
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PP2A-B55 Santa Cruz (sc-18330) Goat 1:1000 (IB) 
 
Table 2.2 Primary antibodies used in project IB, immunoblot; IF, 
immunofluorescence 
 
2.1.5 Secondary antibodies 
	
All horseradish peroxidase (HRP)-conjugated secondary antibodies were 
obtained from Dako/Agilent and stored at 4°C protected from light. 
• Goat anti-rabbit 
• Goat anti-mouse 
• Rabbit anti-goat 
For IF experiments, all secondary antibodies were used at 1:2000. For IB 
experiments, secondary antibodies were used at 1:2500 with the exception of 
detecting α-Tubulin where the concentration of the secondary antibody was 
1:4000. 
 
2.1.6 siRNA 0ligonucleotides 
The names and sources of the siRNA oligonucleotides used are listed in Table 
2.3. Stored at -20°C protected from light. 
 
Target Source (catalogue number) 
Negative Control QIAGEN AllStars (SI03650318) 
PP2A-B55α subunit 
(PPP2R2A) 




QIAGEN FlexiTube (GS55844) 
α-Endosulfine (ENSA) 
Dharmacon ON-TARGET plus SMARTpool 
(L-011852-00-0005) 
ARPP19 (cAMP regulated 
phosphoprotein 19) 
Dharmacon ON-TARGET plus SMARTpool 
(L-015338-00-0005) 
 




2.2.1 Production of lentivirus particles containing shRNA constructs 
	
4.5 µg each of plasmids encoding the viral components VSV-G1 and psPAX2, 
plus 3 µg of either the shGWL or shScr plasmid constructs (depending on which 
viral vector was being made) was diluted in 1.5 mL Opti-MEM™ media (Gibco) 
and mixed gently. In a separate tube, 36 µL Lipofectamine 2000 (Invitrogen) 
was added into 1.5 mL Opti-MEM™ and mixed gently. The Lipofectamine 
mixture was incubated at room temperature for 5 minutes. After this, the viral 
plasmids and the shRNA plasmids were combined with the Lipofectamine 
solution, mixed gently and incubated at room temperature for 20 minutes. 
 
Meanwhile HEK293FT cells were trypsinised and re-suspended at a 
concentration of 1.2 x 106 cells/mL in antibiotic-free DMEM. Then the 
transfection mixture (3 mL total) was added to a 10 cm plate and then 5 ml of 
1.2 x 106 cells/mL were added to give 6 x 106 cells total in 8 ml. The cells and 
transfection mixture were gently combined by rocking the plate and placed in a 
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cell culture incubator. 24 hours later, the media was aspirated and replaced with 
8 ml antibiotic-containing media. 48 hours following transfection, the cells were 
checked for GFP expression. In the event of GFP positive HEK293FT cells, the 
media was carefully harvested and centrifuged at 3000 rpm for 5 min to pellet 
any HEK293FT cells present. The supernatant containing the virus was divided 
into 1 mL cryovials and stored at -80°C. 
 
2.2.2 shRNA-lentivirus based transfection 
	
A small batch of DMEM supplemented with 6 µg/µL Polybrene (Sigma) (to aid 
viral transfection efficiency) was prepared, and to each well of a 6-well plate the 
following viral dilutions were set up (Table 2.3) 
 
Dilution Volume of 
lentivirus titre 
(µL) 
Volume of complete 
DMEM supplemented with 
6 µg/µL Polybrene (µL) 
0 0 1500 
1:3 500 1000 
1:5 300 1200 
1:10 150 1350 
 
Table 2.4 Lentiviral transfection dilutions used in project  
	
	
To each well, a suspension of 50,000 cells/mL in complete DMEM was added. 
The cells and the virus particles were left to incubate for 48-72 hours, and then 
inspected for GFP production. Cells that displayed a good transfection 
efficiency, i.e. glowing green from GFP expression, were harvested and frozen 
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in cryovials at -80°C before being sent to Alice Shea at Bart’s Cancer Institute 
(BCI) for GFP-sorting to select for the population of cells that express the higher 
amounts of GFP. Within the shRNA plasmid, the GFP gene is coupled to the 
Tetracycline Response Element (TRE) via a T2A ribosome-skipping element 
(Figure 3.3). This means the level of GFP expression will be proportional to the 
level of shRNA expression. 
  
2.2.3 siRNA lipid-based transfection 
	
For siRNA-based depletion assays, the transfection reagent Lipofectamine 
RNAiMAX (Invitrogen) was used.  
Per siRNA transfection, 500 µL Opti-MEM™, 5 µL of RNAiMAX and 2.5 µL of 
each appropriate siRNA molecule (Table 2.3) were mixed gently together and 
incubated at room temperature for 15 minutes. This mixture was then added 
dropwise to the well of a 6-well plate containing a freshly counted and re-
suspended solution of cells. 
2.2.4 Total cell extracts 
	
Cells were counted and lysed in a volume of 4x Sample Buffer (Final 
concentration at 1x working dilution 50 mM Tris-HCl pH 6.8, 2% SDS, 10% 
glycerol, 1% β-mercaptoethanol, 12.5 mM EDTA, 0.02% bromophenol blue) 




2.2.5 SDS-PAGE and Immunoblotting 
	
Samples were briefly sonicated with a Vibra-Cell™ sonicator (VWR) to shear 
DNA, and then boiled at 95°C for 5 minutes before separation by SDS-PAGE.  
 
Running gels comprised of 10% bisacrylamide for detection of most proteins 
such as GWL, PP2A-B55 and α-Tubulin; a 15% bisacrylamide gel was used to 
sufficiently resolve ENSA, plus 125 mM Tris-HCl [pH 6.8], 0.1% SDS, 0.1% 
ammonium persulphate (APS) and 0.1% N,N,N',N'- tetramethylethylenediamine 
(TEMED). Resolving gels comprised 10% bisacrylamide, 375 mM Tris-HCl [pH 
8.8], 0.1 % Sodium dodecyl sulphate (SDS), 0.1% Ammonium persulphate 
(APS) and 0.05% TEMED.  
 
A lane of Color Prestained Protein Standard, Broad Range (11–245 kDa) 
marker (New England Biosciences) was included on all gels to confirm band 
sizes and to ensure completion of the electrophoresis protein separation. The 
SDS-PAGE gels were run at 150 V using a PowerPac™ Basic (Bio-Rad) until 
the blue front of the sample buffer had reached the bottom of the gel. 
 
Protein was transferred by a semi-dry transfer onto a Hybond™ PVDF 
membrane (GE Healthcare Amersham) (that had been previously soaked in 
methanol) using a Trans-Blot® Turbo™ (Bio-Rad). The buffers used for the 
semi-dry transfer are listed in Section 2.1.3. 
 
Proteins of interest were detected using the concentrations of primary antibody 
as indicated in Table 2.2 in 5% milk/PBS solution. A loading control was 
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detected using a 1:10,000 dilution of anti α-Tubulin antibody (Abcam) in 5% 
milk/PBS solution. Membranes and primary antibodies were incubated 
overnight at 4°C. 
 
The next day the primary antibody solution was removed, and the membranes 
washed 5 minutes in 0.1% NP-40/PBS x3. After washing, the appropriate HRP-
conjugated secondary antibody (Section 2.1.5) was added to the membranes 
in a 5% milk/PBS solution and incubated at room temperature for 1 hour. After 
this incubation the membrane was washed x3 with 0.1% NP-40/PBS as before 
and then placed in PBS without detergent whilst the chemilluminescence 
substrate was prepared. 
 
2.2.6 Chemilluminescence detection 
	
The chemilluminescence substrate is comprised of:  
• Luminol solution (0.1 M Tris-phosphate [pH 8.6]; 0.5 mg/mL Luminol 
Sodium Salt (Sigma)) 
• Enhancer solution (1.1 mg/mL p-Coumaric acid dissolved in DMSO (both 
from Sigma) 
• Hydrogen peroxide (Fluka) 
And is prepared in the following ratio per mL: 
• Luminol 1 mL 
• Enhancer 10 µL 
• Hydrogen peroxide  3.1 µL 
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The chemilluminescence substrate was added to the membrane, and the 
results analysed by exposing the membrane to X-ray film (Amersham) and 
developed in a Xograph film developer. X-ray film exposure times were varied 
to optimise clarity and exposure of bands present. 
 
2.2.7 Colony formation assay 
	
Feeder layers were made by irradiating 6 x 104 cells per 10cm dish with 35 Gy 
radiation and plating out the cells and incubating them at 37°C, 5% CO2 
overnight to allow cells to adhere. Then fresh cells were counted, plated and 
incubated until discrete colonies could be seen. The media was removed, the 
plates washed with PBS and the cells fixed by adding 2 mL Methanol per plate 
and gently swirling. After aspiration of the Methanol, another PBS wash was 
carried out before staining the cells with 0.05% Crystal Violet solution (0.5 g 
Crystal Violet, 27 mL 37% formaldehyde, 10 mL Methanol in 963 mL PBS). 
After staining, the Crystal Violet was removed by submerging the plates and 
washing under gently running water until all background stain was removed. 
 
2.2.8 Immunofluorescence and EdU staining for fixed cell microscopy 
	
Cells were cultured on glass coverslips. If also staining for EdU, 10 µM EdU 
was added for 20 minutes prior to fixation. Cells were fixed with 1 mL 3.7% 
formaldehyde (Sigma-Aldrich) for 10 minutes at room temperature. Fixed cells 
were washed 3 times with PBS. Cells were then permeabilised with 1% NP-40 
for 15 minutes and washed 3 times with PBS.  
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Optional step: If staining for EdU uptake, an appropriate volume of the Click- 
iT™ cocktail, made according to the manufacturer’s instructions (Click-iT™ EdU 
Alexa Fluor™ 647 Flow Cytometry Assay Kit, Life Technologies) was prepared 
and 40 µL of the Click- iT™ cocktail applied to the coverslip. The coverslips 
were then incubated in the dark at room temperature for 30 minutes, and then 
gently washed twice with PBS. 
 
The slides were then blocked for 30 minutes with 3% BSA/PBS (Sigma-Aldrich). 
Then, incubation with the primary antibody in 3% BSA/PBS for 1 hour at room 
temperature, followed by 2x PBS washes, then secondary antibody (1:2000 
dilution) for 1 hour and then a final 2x PBS washes. Cells were then incubated 
with a 1:1000 DAPI solution in PBS for 10 minutes before being mounted onto 
standard laboratory slides face down using a drop of ProLong™ Diamond 
Antifade Mountant (Life Technologies) and allowed to set for at least 24 hours 
in the dark at room temperature. 
 
2.2.9 Fixed and live cell microscopy 
	
Images of cells were taken with an IX73 Inverted Microscope (Olympus) with a 
40x oil immersion objective (Olympus). Images were collected by µManager 
software (Open Imaging). Fixed cell image figures were prepared with OMERO 
software. Nuclei were counted with ImageJ (NIH) with the Cell Counter plugin. 
 
Movies of living cells were taken with an IX73 Inverted Microscope (Olympus) 
with an IXplore Live incubation chamber to maintain cell viability. Time frames 
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of cells were captured every 5 minutes over a 72-hour period. Cells and their 
divisions were tracked manually with ImageJ (NIH). 
 
2.2.10 EdU labelling for Fluorescence Activated Cell Sorting 
	
10 µM EdU was added for 1 hour prior to cell harvesting. Cells were trypsinised, 
spun down at 1500 rpm for 5 minutes and then washed with PBS before being 
spun down again. Then each sample pellet was re-suspended in 50 µL PBS 
and 750 µL 70% Ethanol and incubated at 4°C overnight. 
 
Cells were spun down at 1500 rpm for 5 minutes and the supernatant removed. 
Then the cells were washed twice with 500 µL of 1% FCS/PBS. After the final 
wash, the pellet was resuspended into 40 µL of the prepared Click-iT™ cocktail, 
made according to the manufacturer’s instructions (Click-iT™ EdU Alexa 
Fluor™ 647 Flow Cytometry Assay Kit, Life Technologies). The reaction was 
allowed to develop in the dark at room temperature for 30 minutes. Cells were 
spun down again at 1500 rpm for 5 minutes, the supernatant removed, and the 
cells washed twice with 500 µL of 1% FCS/PBS, before being spun down again. 
 
The cells were resuspended in 500µL of 1% FCS/PBS containing 5 µg/mL of 
Propidium Iodide (PI) and 250µg/mL of RNase A (Sigma). The PI stain and the 
ribonuclease digestion was left to develop overnight at 4°C. Before FACS 
analysis (Accuri BD Accuri™ C6), the samples were filtered through the cell 
strainer caps of into Falcon 5 mL round bottom polystyrene test tubes (Scientific 
Laboratory Supplies). 
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2.2.11 Generating GWL shRNA MDA-MB-231 cells expressing DHB-
mCherry 
The CSIIefAH-DHBVen vector (generously gifted from Sabrina Spencer) was 
digested with BamH1 to remove the mVenus tag and the coding sequence for 
mCherry was cloned into this site by Gibson assembly. Correct integration and 
absence of PCR related mutations were checked by DNA sequencing. Using 
the CSIIefAH-DHBmCherry plasmid we generated lentiviral particles in 293FT 
cells and infected the GWL shRNA MDA-MB-231 cells. Positive clones were 
isolated by FACS sorting and expression of DHV-mCherry was confirmed by 
fluorescent microscopy. 
 
2.2.12 Analysing CDK2 activity using the DHB-mCherry probe 
DHBmCherry expressing GWLshRNA MDA-MB-231 cells were either treated 
with 2 µg/mL Dox or left in Dox free medium. Following three days of shRNA 
induction the cells were plated on 96 well plates (Cell carrier, Perkin Elmer). 2 
wells were used for Control and 2 for Dox treated cells. Lee011 was then added 
at 0.5 µM to one of the control wells and one of the + Dox wells. To obtain a 
counterstain, the cells were also treated with 0.5 µM SiR-DNA (Cytoskeleton, 
Inc.). Imaging was performed on an Operetta high throughput imaging device 
(Perkin Elmer) using a 40x water lens (NA=1.1). Time-lapse microscopy was 
performed at 10-minute intervals and 25 positions per well were imaged for 25 
hours. For analysis, the images were exported and regions of interest (ROI) 
inside and outside the nucleus were measured manually in ImageJ in hourly 
intervals. With the help of Helfrid Hochegger, the data were imported as Pandas 
data frames and further analysed using Python 3.7. Graphs were generated 
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using the Python Seaborn methods package. For Figure 6.5B, there is some 
qualitative analysis, and levels of CDK2 activity are judged by eye which is 
demonstrated in Figure 6.5C. The medium CDK2 activity is when there is no 
discernable difference in fluorescence between inside and outside the nucleus. 
High CDK2 activity is when the cytoplasm shows high fluorescence and there is 
no fluorescence in the nucleus. Low CDK2 activity is when the nucleus clearly 
shows higher fluorescence than the cytoplasm. 
 
2.2.13 Publicly available datasets 
Information regarding mRNA expression of GWL in different molecular subtypes 
of breast cancer and the Kaplan-Meier plot plotting survival probability against 
GWL expression in breast cancer were obtained from: 
http://tumorsurvival.org/TCGA/Breast_TCGA_BRCA/. Additional Kaplan-Meir 
plots plotting survival probability against GWL expression in a pan-cancer wide 
study (PANCAN) as well as just breast cancer were obtained from 
https://xenabrowser.net/. GO analysis was carried out by the PANTHER 
classification system at www.pantherdb.org. 
 
2.2.14 Statistical analysis 
Statistical tests were performed with GraphPad Prism version 5.0. P values 
were two-tailed and considered significant if P < 0.05. Error bars represent SEM 
of three independent experiments, unless otherwise stated. Certain figures 
show two independent replicates and error bars of SEM, but without statistical 
tests. Such cases are indicated in the figure legends. The Estimation Statistics 
analysis (Shared Control) shown in Chapter 5 was carried out using the 
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following open source tool: http://www.estimationstats.com/#/analyze/shared-




Chapter 3. Characterisation of Greatwall kinase depletion in 
Triple Negative Breast Cancer cells 
3.1 Introduction: Greatwall Kinase and cancer 
	
The function of GWL as an essential mitotic kinase has been extensively 
characterized in Drosophila, Xenopus, and mammalian cells (J. Yu et al. 2004; 
Vigneron et al. 2009; Burgess et al. 2010; Álvarez-Fernández et al. 2013). In 
addition, previous studies have published thorough characterisations of GWL 
function, localisation and depletion phenotypes in human cancer cells.  The 
human GWL protein appears to be essential for development (Álvarez-
Fernández et al. 2013) is stably expressed throughout the cell cycle but is 
phosphorylated and most active during mitosis (Dephoure et al. 2008; Voets & 
Wolthuis 2010; Olsen et al. 2010).  
 
More recently while this thesis was in preparation, there have been studies 
published regarding the role of GWL and its depletion phenotypes in human 
breast cancer cells which suggest that GWL may have clinical importance both 
as a potential therapeutic target and as a prognostic tool (Vera et al. 2015; 
Álvarez-Fernández et al. 2013; Álvarez-Fernández, Sanz-Flores, Sanz-Castillo, 
Salazar-Roa, Partida, Zapatero-Solana, Ali, Manchado, Lowe, VanArsdale, 
Shields, Caldas, Quintela-Fandino & Malumbres 2018b; Rogers et al. 2018). 
These studies have shown that GWL is often overexpressed in a range of 
human cancers, including breast cancer (L. Wang et al. 2014; Rogers et al. 
2018), and that overexpressing GWL in non-cancerous cells can promote some 
of the transformational properties needed for cells to eventually become 
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cancerous such as AKT hyper phosphorylation (Vera et al. 2015). It has also 
been shown that GWL protein expression levels can vary dramatically across 
different Breast Cancer cell lines (Álvarez-Fernández, Sanz-Flores, Sanz-
Castillo, Salazar-Roa, Partida, Zapatero-Solana, Ali, Manchado, Lowe, 
VanArsdale, Shields, Caldas, Quintela-Fandino & Malumbres 2018b) and 
Squamous Cell Carcinoma (SCC) cell lines (L. Wang et al. 2014). GWL 
overexpression also encouraged transforming behaviour in immortalised, non-
transformed cells and can increase in vitro and in vivo tumour cell proliferation 
(Vera et al. 2015). It is, thus, tempting to speculate be that GWL is not only 
required to maintain CDK1 activity during a normal, unperturbed cell cycle, but 
can also be high jacked by tumour cells to supress the downstream activity of 
the phosphatase complex PP2A-B55. It is important to note that PP2A has 
been implicated as a tumour suppressor (Janssens et al. 2005; Manchado et al. 
2010; Álvarez-Fernández, Sanz-Flores, Sanz-Castillo, Salazar-Roa, Partida, 
Zapatero-Solana, Ali, Manchado, Lowe, VanArsdale, Shields, Caldas, Quintela-
Fandino & Malumbres 2018b). Alternatively, overexpression of GWL may 
simply help in boosting CDK1 activity during checkpoint recovery following cell 
cycle arrest after DNA damage events (Peng et al. 2010). Thus, it could be 
possible that cancer cells, being more genetically damaged and unstable than 
normal cells, are more reliant on GWL. Overall, a link between GWL 
overexpression and tumourigenesis is starting to emerge, however does require 




3.2 Greatwall kinase over expression in triple negative breast cancer 
	
I performed an analysis of clinical data from breast cancer patients confirms the 
previously mentioned published reports that there is a link between GWL 
expression and patient survival. Using publicly available data from The Cancer 
Genome Atlas (TCGA) databases and the web tools 
http://tumorsurvival.org/index.html and https://xenabrowser.net/; this data can 
be seen in Figure 3.1. Looking exclusively at breast cancer, the Basal/Triple 
Negative subtypes show the highest amount of GWL mRNA expression 
according to RNA-Seq. Across all breast tumour types sampled as well as a 
survey of all tumour types via the PANCAN study, the tumours that graded 
‘high’ in GWL expression were associated with shorter survival (Fig. 3.1).  
 
To analyse the role of GWL in cancer cells I chose TNBC cells as a model 
system due the strong link of this tumour class with GWL over expression (Fig. 
3.1) (Álvarez-Fernández, Sanz-Flores, Sanz-Castillo, Salazar-Roa, Partida, 
Zapatero-Solana, Ali, Manchado, Lowe, VanArsdale, Shields, Caldas, Quintela-
Fandino & Malumbres 2018b; Rogers et al. 2018) and the therapeutic need due 
to TNBC exhibiting a high degree of heterogeneity and lacking well-defined 
therapeutic targets, meaning that this tumour type is associated with poor 
prognosis (Dent et al. 2007; Haffty et al. 2006; Bianchini et al. 2016). 
 
Cell line  Origin 
MDA-MB-231 
Breast (adenocarcinoma; Triple 
Negative; Basal B) 
MDA-MB-436 
Breast (invasive ductal carcinoma; Triple 
Negative; Basal B) 
 83 
MDA-MB-468 
Breast (adenocarcinoma; Triple 
Negative; Basal A) 
HS578T 
Breast (carcinosarcoma; Triple Negative; 
Basal B) 
MCF10a 
Breast (immortalised fibrocystic 
epithelia) 
 
Table 3.1: Cell lines used in project Information about the phenotype of the 
cell lines was obtained from the American Type Culture Collection and a study 
by Chavez et al. (Chavez et al. 2010). 
 
Our collaborator, Chris Lord of the Institute of Cancer Research (ICR), London, 
generated additional preliminary data for this project. A high-throughput siRNA-
GWL screen was set up to measure cell viability after GWL depletion in a large 
panel of human cell lines, mostly cancerous cells, from a variety of organs and 
molecular subtypes within cancers of the same organ. The waterfall plot 
showing the Z-scores of the cell viabilities following GWL depletion as well as 
the table showing the identity of each cell line used and its corresponding Z-
score is shown in Figure 3.2. The waterfall plot (Fig. 3.2A) indicates that there 
is a subset of cancer cells that are highly sensitive to GWL depletion, whilst 
there are other cells that are tolerant of this. Cancerous cells from a range of 
organs show sensitivity and resistance to GWL depletion, so this raises the 









Figure 3.1 Clinical data from The Cancer Genome Atlas database 
shows a correlation between GWL overexpression and lower survival 
probability Red lines in survival plots signify GWL overexpression A) 
GWL (here as MASTL) mRNA expression across different breast cancer 
types B) Survival of patients with all breast tumour subtypes correlated 
with GWL mRNA expression C) Survival of patients with Basal (Triple Neg-
ative) breast tumours correlated with GWL mRNA expression D) PANCAN 
database (all tumour types) correlating patient survival with GWL expres-




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.2 A siRNA screen deplet-
ing GWL in a panel of human 
cancer cell lines indicates a thera-
peutic window Experiment by Chris 
Lord, ICR. A panel of human cancer 
cell lines was treated with GWL siRNA 
and their viability was assessed with 
CellTiter-Glo® assay. A) Cell viability 
was plotted as a Z-score B) List of cell 
lines and their corresponding Z-score. 
TNBC cell lines are highlighted in 
orange, and the hormone receptor 
positive and/or HER2 positive breast 
cancer cell lines are highlighted in 
green. The non-transformed human 
breast cell lines MCF10A and 






As a first step in characterising GWL kinase in TNBC, I examined whether 
differences in GWL protein levels exist across a panel of TNBC cells and a non-
transformed breast epithelial cell line.  Four TNBC cell lines were used – MDA-
MB-231 (MDA-MB-231), HS578T, MDA-MB-436 (MDA-MB-436), MDA-MB-468 
(MDA-MB-468) and the non-cancerous breast cell line MCF10a. These cell 
lines are commonly used in cell culture and are well characterised, and more 
information about these cells can be found in Table 3.1.  
 
Asynchronous whole cell extracts prepared from each of the five cell lines were 
analysed by Immunoblotting using antibodies against GWL and α-Tubulin, 
where α-Tubulin was used as a loading control. In Fig. 3.3 the immunoblot 
bands that indicate GWL are the bands that are found nearest the 100 
kilodalton (kDa) mark. The slightly lower bands that can be seen are believed to 
be non-specific. They do appear inconsistently in different blots and their 
appearance is not affected by siRNA or shRNA depletion. However, we cannot 
exclude that these bands constitute splicing variants of the kinase. A theoretical 
splicing variant with a size of 92 kDa is indeed documented in the UniProt 
database. Fig. 3.3 clearly indicates that the TNBC cells have higher levels of 
GWL than the non-transformed MCF10a cells, which is in agreement with 
another study of breast cancer cells (Rogers et al. 2018) and also from data 
from cells of a different organ, SCC cells, where the non-transformed 
keratinocyte lines showed lower GWL protein levels than the SCC cell lines (L. 
































Figure 3.3 Expression of GWL in asynchronous human breast 
cell lines SDS-PAGE analysis of a panel of Triple Negative Breast 
Cancer cell lines as well as the non-transformed breast epithelial cell 
line MCF10a. Greatwall kinase expression levels were detected using 
the anti-Greatwall kinase antibody, and an anti-α-Tubulin antibody was 

























B) 3 days 
C) 5 days 
D) 7 days
Fig. 3.4 Vector map of the inducible shRNA system and time course 
immunoblot depicting the knockdown of GWL A) Vector map of the plas-
mid containing the GWL-shRNA and GFP reporter gene. B)-D) SDS-PAGE 
analysis of the Doxycycline-inducible shRNA system to deplete GWL in 
MDA-MB-231 cells. A final concentration of 2 µg/mL Doxycycline was used 
to induce shRNA expression. B) GWL levels after 3 days of shRNA induc-








shRNA - - ++
Scr Gwl
- - ++






Fig 3.5 Testing the inducible shRNA system in 
HS578T cells SDS-PAGE analysis of the Doxycy-
cline-inducible shRNA system to deplete GWL in 
HS578T cells. A final concentration of 2 µg/mL Dox-
ycycline was used to induce shRNA expression.  
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3.3 A stable, Doxycycline-inducible shRNA system to study Greatwall 
kinase depletion 
GWL has been shown to be essential in HeLa cells (Burgess et al. 2010; Voets 
& Wolthuis 2010). In mice, heterozygous mutants for functional GWL are viable 
and fertile but the homozygous knockout GWL mutants are embryonic lethal 
(Álvarez-Fernández et al. 2013).  In the mammalian cell experiments in this 
paper, GWL appeared to be non-essential for mitotic entry alone (Álvarez-
Fernández et al. 2013), but critical for long-term proliferation. Therefore, a 
conditional depletion approach is necessary for a comprehensive genetic 
analysis of GWL in in TNBC cells with a view to improve therapeutic knowledge. 
We decided to employ inducible shRNA expression as our method of choice for 
conditional depletion. Short hairpin RNA (shRNA) mediated knockdown 
methods have the advantage of having a lower turnover than siRNA and stably 
integrating the expression construct into the target genome for long-term 
expression. The use of a ‘Tet-On’ shRNA system with Doxycycline (Dox) allows 
for easy knockdown of GWL that is amenable for experiments that explore the 
effects of GWL depletion in a well-controlled and permanent manner.  
 
We used a shRNA expression system published by Sigl et al. (Sigl et al. 2014). 
In this lentiviral construct, Green Fluorescent Protein (GFP) is coupled to a 
doxycycline-regulated transactivator protein (Tet-on) via a T2A ribosome-
skipping element (Donnelly et al. 2001). This permitted fluorescence-based cell 
sorting of the cells with highest levels of Tet-on protein and is also useful for 
periodically checking that the cells had not rejected or deleted the construct 
from the genome. The shRNA is expressed from a promoter that is controlled 
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by a Tetracycline Response Element (TRE). Thus, addition of doxycycline 
allows expression of the shRNA and induces depletion of the target protein. The 
GWL shRNA sequence was cloned into this construct by a previous graduate 
student, Clare Vesely (unpublished results). The vector map can be seen in Fig. 
3.4. 
 
HEK293T cells were used to assemble the viral components into virus particles 
encasing the shRNA construct using a lipofectamine based transfection 
protocol. Wild-type cell lines were infected with the shRNA-containing lentivirus 
with the help of Polybrene. Full virus assembly and cell transfection protocols 
are found in Chapter 2 – Materials and Methods. Inclusion of a GFP reporter 
meant that following cell infection with lentivirus, selection of infected cells was 
carried out using two rounds of Fluorescence Activated Cell Sorting (FACS) to 
select and grow the cells expressing the shRNA construct the highest, to ensure 
the strongest possible GWL knockdown. Alice Shea at Bart’s Cancer Institute 
(BCI) carried out the GFP FACS sorting, and cells were screened for 
Mycoplasma contamination before culture and use in experiments. 
 
The next step was to test the efficacy of the shRNA-mediated GWL knockdown, 
as well as the Scr control by immunoblotting. In Fig. 3.4 panels B to D show 
how the levels of GWL protein in MDA-MB-231 cells are decreased after 3 days 
exposure to 2 µg/mL Dox, and are undetectable by immunoblot after 5 days 
exposure, and this depletion is maintained after 7 days. Figs. 3.4B and C show 
most clearly how the presence of Dox in the Scr-shRNA cells does not affect 
the GWL protein levels. The decrease in GWL protein level in Fig. 3.4A in the 
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Scr + Dox lane is due to my unequal cell lysate loading, as shown by the 
corresponding α-Tubulin level. Fig. 3.5 also shows that the shRNA-mediated 
knockdown of GWL works well in HS578T cells, the Scr-shRNA also does not 
affect GWL protein levels, and there is no detectable GWL protein after 7 days 
of shRNA induction. 
 
To ensure that the shRNA-mediated depletion of GWL was effective and 
consistent, I used three separate immunoblots using three different cell extracts 
from each cell line to quantify the effectiveness of the GWL knockdown (Figure 
3.6). Using the Image Studio Lite software (LI-COR Biosciences), I measured 
the band intensity of the bands corresponding to the shGWL no Dox lanes and 
the intensity of the bands corresponding to the shGWL plus Dox lanes. I then 
normalised these band intensity levels to the intensity of their corresponding α-
Tubulin loading control bands. This allowed me to ensure that quantification of 
the immunoblot signal was linearly related to protein quantity and so was as 































































Figure 3.6 Quantifying the efficiency of the shRNA-mediated GWL 
knockdown in a panel of TNBC cells Panels i) to iii) are representative 
immunoblots of the indicated cell lines. iv) Quantification of the efficiency of 
the GWL knockdown. Each GWL + Dox knockdown lane was normalised to 
the corresponding loading control lane. N=3 biological repeats were used 
to generate the data. The error bars represent the Standard Error of the 








3.4 Characterisation of Greatwall kinase depletion in human breast cells 
	
Once it was established that the Doxycycline-inducible shRNA system to 
deplete GWL was effective, the next step was to look for GWL-loss phenotypes 
in the TNBC cells. Colony formation assays were used to assess the effect of 
GWL depletion on cell growth and survival over an extended period of time. 
Onto a layer of irradiated, senescent feeder cells in a 10 cm cell culture dish, 
1000 live cells were plated with or without Dox treatment. After two weeks, with 
fresh Doxycycline being added every week, the cells were stained with Crystal 
Violet solution and the dishes photographed, and the number of colonies 
counted (Fig 3.7). I found that the cell lines MDA-MB-231 and HS578T were 
sensitive to GWL depletion in this context (Fig. 3.7i) to viii), with the GWL 
shRNA + Dox plates growing considerably less colonies than the three control 
plates. The MDA-MB-436 cells did not appear to suffer under this example of 
GWL depletion, with the GWL shRNA + Dox plate growing just as many 
colonies as the control plates. To quantify these results more thoroughly in 
addition to the representative photographs, I counted the number of colonies on 
each plate for each replicate. I then took the average counts for the Scr shRNA 
- Dox cell lines and set these averages as 1.0 in order to normalise the counts 
for the Scr + Dox cell lines and the GWL + Dox cell lines against their 
corresponding Scr - Dox counterparts (Fig. 3.7xiii). Counting the colonies and 
normalising to Scr - Dox shows that the MDA-MB-231 and HS578T cells are 
consistently sensitive to GWL loss, and the MDA-MB-436 cells are consistently 




i) Scr - ii) Scr + Dox
iii) Gwl - iv) Gwl + Dox
ix) Scr - x) Scr + Dox
xi) Gwl - xii) Gwl + Dox
MDA-MB-436
MDA-MB-231
v) Scr - vi) Scr + Dox
vii) Gwl - viii) Gwl + Dox
HS578T
Figure 3.7 Quantifying the shRNA 
induced GWL depletion using 
Colony Formation Assays Per 10 
cm plate, 1000 live cells were 
seeded onto an irradiated feeder 
layer of 60,000 cells and incubated 
for two weeks prior to staining with 
0.05% Crystal Violet solution. Panel 
xiii) shows the colony counts where 
the counts of the GWL shRNA lines 
+Dox plates are normalised to the 




























































































Figure 3.8 Analysing the effect of GWL knockdown on 
MCF10a cells i) Per 10 cm plate, 1000 live cells were seeded 
onto an irradiated feeder layer of 60,000 cells and incubated for 
two weeks prior to staining with 0.05% Crystal Violet solution. ii) 
Represents the mean counts of N=3 colony formation assay 
experiments. Error bars are SEM. iii) Representative immunob-
lot of the MCF10a GWL knockdown
iii)
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This experiment was also carried out in MCF10a GWL shRNA cells, and the 
resulting colonies counted (Fig. 3.8). The GWL knockdown did have an 
intermediate effect on the colony growth of the cells, and there is a clear 
difference between the control and the Dox treated plates. Fig. 3.8C shows the 
knockdown of GWL in MCF10a GWL-shRNA cells after 7 days. The 
establishment of a Scr-shRNA control for the MCF10a cell line was attempted 
throughout this project but was unsuccessful and so this control is currently 
missing. 
 
The next phase of the characterisation of GWL phenotypes in these cell lines 
was to look at the effect of GWL depletion on mitosis and the cell cycle using 
live cell microscopy (Figures 3.9 – 3.11). Filming live cells enabled me to 
observe when in the cell cycle the GWL knockdown caused problems, if any, 
and if so what the consequences of such problems are for these cells. Using 
the level of GWL knockdown shown in the time course immunoblots in Figs. 3.4 
and 3.5 as a reference, of the cells that were treated with Dox to induce GWL 
knockdown, these cells received the Dox treatment 48 hours prior to the start of 
filming. This ensured that GWL was beginning to be knocked down, so that I 
could see how the cells coped with the loss of GWL during imaging, rather than 
filming the aftermath, which may have been too late to observe how any 
phenotypes emerged. Fig. 3.9A and B show the results of a 50-hour filming 
period using MDA-MB-231 cells that had not been treated with Dox, and MDA-
MB-231 cells that had been treated with Dox, respectively. The control cells in 
Fig. 3.9A consistently divide twice within the filming period with no significant 
mitotic problems. One triple division was observed, which is a normal feature of 
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cancerous cells. In the GWL knockdown movie using MDA-MB-231 cells (Fig. 
3.9B), only two out of the ten cells tracked had daughter cells that divided again 
during filming. The other cells either did not divide again, or if they attempted 
mitosis, the mitosis time was longer (as shown by the length of the red bars 
representing M phase), or the cells showed cytokinesis failure or apoptosis. 
With the HS578T cells (Fig. 3.10), the control cells (Fig. 3.10A) more often than 
not divided only once during filming because most of the traceable cells did not 
divide until some way into the filming process, meaning that the second division 
was not able to be recorded. There was one cell that could be tracked early on 
in the movie whose daughter cells both divided, so like with the MDA-MB-231 
cells it is possible for a HS578T cell to divide twice within 50 hours. In contrast, 
in the + Dox group (Fig. 3.10B), half of the cells underwent apoptosis after 
attempting mitosis. Some cells divided as normal, but there were no second 
divisions from their daughter cells. The third set of movies, shown in Fig. 3.11 
used the non-cancerous MCF10a cells. In the control movie (Fig. 3.11A), the 
MCF10a cells completed two rounds of mitosis without any significant problems. 
Most of these cells seemed to manage two divisions quickly, within the first 30 
hours of filming, and then did not divide again. When GWL was depleted (Fig. 
3.11B), just over half the cells seem to be unaffected, whilst the remainder did 
not undergo a second round of mitosis. Taking this information into account 
when looking at the colony formation assays, this suggests that in the MCF10a 
cell line when GWL is knocked down, the reduction in colony number seen 
could be due to the cells entering a quiescent or senescent state. This is in 
contrast with the MDA-MB-231 and HS578T cells that also show reduction in 
colony number after GWL knockdown but exhibited apoptosis during live cell 
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imaging. The difference could be that in the MCF10a cells, the cells cease 
dividing after GWL depletion, but in the MDA-MB-231 and HS578T cells, these 
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Table 3.2 A count of the number of cells in the live cell imaging (Figures 




The number of cells that divided, and how often they divided, was counted; 
along with the number of cells that experienced cell death or failed divisions. 
This information is in Table 3.2. This helps to summarise the events in Figs 3.9-
3.11, as it is clearer that the reduction in proliferation in the GWL depleted cells 
is due most of the tracked cells dividing once, and then not dividing again, 
rather than population depletion by cell deaths. Even with GWL depletion, the 
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MCF10a cells were more capable of undergoing two rounds of mitosis within 
the time frame compared to the two breast cancer cell lines. Only a few 
observed MDA-MB-231 and HS578T cells were seen committing a clear cell 
death, and cell death did not occur in any of the tracked MCF10a cells. The 
MDA-MB-231 cells with no GWL knockdown were the most proliferative, 
whereas the equivalent no Dox HS578T cells in this experiment were less likely 
to divide twice during filming. 
 
A comparison of the mitotic time lengths between control and GWL depleted 
cells, and across the different cell lines is shown in Figure 3.12. The mitotic 
time was only recorded for cells that clearly and successfully completed mitosis, 
including cytokinesis. As a result, there are less data points in the GWL 
depleted conditions in all three cell lines tested, because there were fewer 
mitotic events. GWL knockdown caused a slight trend of increasing the length 
of time cells spent in mitosis, but the wide range in mitotic times and fewer 
mitotic events in GWL depleted cells makes this feature difficult to evaluate with 
this data alone. However, Figure 3.12 suggests that GWL depletion is not 
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Figure 3.9 Investigating GWL depletion with live cell imaging in 
MDA-MB-231 cells Cells were plated onto a 2-well imaging chamber 48 hours 
prior to filming, and Dox added to one well to represent the GWL knockdown 
treatment.  A) Frames of two representative cells undergoing mitosis with 10 μ
M scale bar B) No Dox control C) GWL knockdown / plus Dox treatment. The 
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Figure 3.10 Investigating GWL depletion with live cell imaging in HS578T 
cells Cells were plated onto a 2-well imaging chamber 48 hours prior to film-
ing, and Dox added to one well to represent the GWL knockdown treatment. A) 
Frames of two representative cells undergoing mitosis with 10 μM scale bar B) 
No Dox control C) GWL knockdown / plus Dox treatment. The horizontal red 































65h32h 30m16h 15m 48h 45m
Time
*cell crawls out of frame




Figure 3.11 Investigating GWL depletion with live cell imaging in 
MCF10a cells Cells were plated onto a 2-well imaging chamber 48 hours 
prior to filming, and Dox added to one well to represent the GWL knock-
down treatment.  A) No Dox control B) GWL knockdown / plus Dox treat-





Figure 3.12 Plotting the duration of mitosis from live cell imaging
The length of time spent in a rounded up, mitotic state was recorded for each 
cell in Figures 3.9-3.11 that completed mitosis successfully. A) MDA-MB-231 
cells, with and without Dox B) HS578T cells, with and without Dox C) MCF10a 
cells, with and without Dox. Not every cell successfully completed mitosis, 
and there are less data points for +Dox experiments, because cells with 










































































































To investigate how GWL depletion was affecting the cell cycle, I set up a series 
of fixed cell immunofluorescence (IF) experiments and analysed the images 
with ScanR software. Microscope slides were prepared after 3 days of Dox 
treatment, and further slides were made for each subsequent day to document 
the progressive effect of the GWL knockdown up to day 7 as well as a no Dox 
treatment control. Prior to cell fixing, I pulse labelled the cells with the modified 
nucleotide EdU followed by counter staining with an anti-CENPF antibody and 
DAPI nuclear stain. More details on this protocol are included in Chapter 2 – 
Materials and Methods. I imaged the slides on an Olympus IX-73 microscope 
with a 40x objective and used Micro-Manager software to instruct the computer 
and microscope to capture images in a 5 x 5 grid shape (25 images in total). 
This meant that 25 images containing thousands of cells in total could be 
analysed quickly and precisely with the ScanR software. The ScanR analysis 
was able to classify cells into cell cycle phases once appropriate detection 
thresholds were set. 
 
If a cell was EdU positive it was in S phase, if it was CENPF positive it was in 
G2/M phase (Bomont et al. 2005; Loftus et al. 2017), and cells that were 
negative for both of these markers were in G1 phase. M phase is included as 
‘G2/M’ in the analysis as CENPF is not degraded until late mitosis, mitotic cells 
represent only about 5% of a cell culture population, and many mitotic cells are 
washed off during the fixing process due to their rounding up. There were 2 
biological replicates for this experiment but there should be reliability to the data 
due to the large number of cells counted. Fig. 3.13 shows the data for this 
experiment using MDA-MB-231 cells. As the GWL protein begins to be knocked 
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down from Day 3 and as this depletion continues, the population of G1 phase 
cells increases and the S- and G2- phase populations decrease. This is most 
noticeable at Days 6 and 7 of Dox treatment. This data suggests that GWL 
knockdown causes prolonged G1 phase, rather than the expected increase in 
the G2/M population. This is curious, as current literature suggests that the 
most likely consequence of GWL depletion in human cells is G2 arrest (Burgess 
et al. 2010). I also chose to analyse the mean nuclear size and intensity of EdU 
staining after noticing that cells that had experienced GWL knockdown were 
often increased in size, and that in the EdU positive cells, the EdU staining itself 
seemed to be less bright. ScanR analyses was set up to measure nuclear size 
from the area of DAPI staining, and the average intensity of EdU staining per 
microscopy image. From the raw data I normalised each day of Dox treatment 
to the no treatment control. The graphs in Fig. 3.13B and C show the results of 
these analyses. Fig. 3.13B shows the results of the mean nuclear size analysis, 
and as GWL is depleted, the mean nuclear size increases. Fig. 3.13C shows 
that as GWL is depleted, the mean EdU staining intensity decreases in the 
remaining EdU positive population. Thus, in addition to a reduction in EdU 
positive/S phase cells in GWL depleted cells (Fig. 3.13A), the incorporation rate 
of EdU is dramatically reduced in the remaining S phase population. This 
suggests that the uptake of the EdU nucleotide, and thus DNA synthesis, might 
be happening at a slower or reduced rate compared to the control cells. 
 
As an additional check to see if GWL knockdown was affecting entry into the 
cell cycle and the rate of cell proliferation, in MDA-MB-231 and HS578T shGWL 
cells I depleted GWL with Dox for 7 days before EdU pulse labelling, cell fixing 
 107 
and processing. I then counted the total nuclei per image as well as the number 
of EdU positive cells with the aid of the ImageJ Cell Counter plugin to reduce 
human error. At least 200 cells were counted under each condition, and three 
biological replicates were made. The results from these experiments are shown 
in Fig. 3.14. In both the MDA-MB-231 and HS578T cells, a reduction in the EdU 
positive populations were seen after 7 days of GWL knockdown. To analyse the 
difference between the control cells and the cells treated with Dox, I carried out 
an unpaired t-test using GraphPad Prism software. Both MDA-MB-231 and 
HS578T cells showed significant differences in the S phase population, but this 




































































































































Figure 3.13 Using IF and ScanR analysis software to analyse effect of 
GWL depletion on cell cycle phase populations in MDA-MB-231 cells A) 
Using EdU as the S-phase marker and CENPF as the G2/M marker, cells were 
classified into cell cycle phases. B) Nuclear size determined by size of DAPI 
stain and normalised to the no treatment control. C) Mean EdU intensity 







Figure 3.14 Analysing effect of GWL knockdown on S-phase population 
with fixed cell IF Cells were treated for 7 days with or without Dox and treated 
with 10μM EdU for 20 minutes prior to fixation with 3.7% paraformaldehyde. 
Fixed cells were stained for S-Phase cells with Click-iT® EdU Alexa Fluor® 
647 kit, pH2AX (red) and DAPI (blue). A) Representative image of 
MDA-MB-231 cells 20x magnification B) Representative image of HS578T 
cells 20x magnification. C) Swarm plot of the EdU positive cells counted in 
MDA-MB-231 cells. D) Swarm plot of the EdU positive cells counted in 
HS578T cells. Unpaired t-test used to analyse the size of the difference in EdU 






























































3.5 Conclusions and discussion 
	
Here I tested a stable, Dox-inducible shRNA system to knock down GWL. This 
system allowed me to look for potential phenotypes of GWL depletion in a way 
that was simple to control and was effective over the course of a week (or 
longer with the addition of fresh Dox to the cell culture media). 
 
I found that there are differences in GWL sensitivity between some different 
TNBC cell lines tested in the context of colony formation assays, live and fixed 
cell microscopy. The MDA-MB-231 and HS578T cells are highly sensitive to 
GWL loss, and in contrast the MDA-MB-436 cells are not sensitive to GWL loss. 
The non-cancerous breast epithelial cell line MCF10a also showed sensitivity to 
GWL knockdown. Previous work using cancer cell lines support this work, with 
evidence of GWL knockdown causing mitotic problems, cell cycle arrest and cell 
death (Burgess et al. 2010; Voets & Wolthuis 2010). The observation that the 
MDA-MB-231 cells are highly sensitive to GWL loss has also been recorded by 
(Álvarez-Fernández, Sanz-Flores, Sanz-Castillo, Salazar-Roa, Partida, 
Zapatero-Solana, Ali, Manchado, Lowe, VanArsdale, Shields, Caldas, Quintela-
Fandino & Malumbres 2018b). Since GWL appears to have an important role in 
suppressing PP2A activity to ensure a timely completion of mitosis, it is not too 
surprising that GWL knockdown has deleterious effects on the non-cancerous 
cell line MCF10a. Though it remains to be elucidated under which contexts 
GWL is most important, as the urgency of GWL necessity may vary depending 
on developmental stage and cell type. In the live cell imaging however, this 
revealed that whilst the MDA-MB-231 and HS578T cells could either commit 
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apoptosis or stop dividing, the MCF10a cells did not show a similar response to 
acute GWL depletion.  
 
In the siRNA GWL screen assessing cell viability when GWL is knocked down, 
Fig. 3.2B flags the TNBC cell line MDA-MB-231 as not sensitive to GWL 
depletion (Z-score 0.699). Based on the work in this chapter, as well this study 
showing that MDA-MB-231 cells show sensitivity to GWL loss (Álvarez-
Fernández, Sanz-Flores, Sanz-Castillo, Salazar-Roa, Partida, Zapatero-Solana, 
Ali, Manchado, Lowe, VanArsdale, Shields, Caldas, Quintela-Fandino & 
Malumbres 2018b), then it is more plausible that the siRNA screen has some 
false positives and negatives and so the results should be interpreted with 
caution. 
 
The most surprising finding of the work presented here is that the main effect of 
GWL depletion in MDA-MB-231 and HS578T cells appears to be on the G1 
population. This is not the first reporting of a non-mitotic role in the GWL 
pathway. A recent study found that knocking down one of the downstream 
substrates of GWL, α-endosulfine (ENSA), caused a lengthening of S phase 
and reduced the density of replication forks in HeLa and U2OS cells (Charrasse 
et al. 2017). This phenotype was also seen when GWL was knocked down and 
was associated with a decrease in Treslin protein levels. Treslin helps to 
regulate DNA replication initiation via its interaction with TOPBP1 by 
participating in CDK2-mediated loading of CDC45L onto replication origins. The 
authors also found increased time spent in S phase was also rescued by 
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overexpression of Treslin when ENSA was knocked down and also that ENSA 
was located in the nucleus during S phase (Charrasse et al. 2017).	
 
However, there are caveats to the work done in this chapter. In these 
experiments only one shRNA sequence was used, which means that any 
resulting cell phenotypes following shRNA induction could be as a result of off-
target effects. Though in Chapter 5, an inducible CRISPR-GWL MDA-MB-231 
cell line was tested. The results obtained from this cell line are in agreement 
with the results obtained from the shRNA-GWL MDA-MB-231 cell line. The 
relative lack of efficacy of the MDA-MB-436 shGWL knockdown in comparison 
to the high effectiveness of that seen in the MDA-MB-231 and HS578T cells is 
concerning (Fig. 3.7). Perhaps GWL has a powerful kinase activity that means 
that only a few GWL molecules are enough to inhibit PP2A effectively in a cell. 
This chapter also lacks analysis with a Scr-shRNA MCF10a cell line, however 
another study found that both knockdown and knockout of GWL in MCF10a 
cells also impaired their proliferation (Álvarez-Fernández, Sanz-Flores, Sanz-
Castillo, Salazar-Roa, Partida, Zapatero-Solana, Ali, Manchado, Lowe, 
VanArsdale, Shields, Caldas, Quintela-Fandino & Malumbres 2018b). Another 
study reported in their experiments that the MCF10a cell line was less sensitive 
to GWL depletion to the breast cancer cell lines tested according to levels of 
cleaved PARP, cell viability assay and cell cycle analysis (Yoon, Choe, Jung, 
Hwang, Oh & J.-S. Kim 2018b). 
 
A study that used a hyperactive version of GWL (the K72M mutant) has shown 
to encourage transforming behaviours such as overcoming cell-cell contact 
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inhibition and anchorage-independent growth (Vera et al. 2015) so it is not 
unreasonable to think that GWL knockdown has an anti-tumourigenic effect. To 
investigate further the difference in the S phase population and in EdU 
nucleotide uptake when GWL is knocked down it would be useful as a next step 
to analyse replication fork speed with DNA fibre assays and length of S phase 
with FACS analysis following thymidine release as per the experiments in 
(Charrasse et al. 2017). 
 
Taken together, the data presented here indicate that GWL may have a more 
significant role in cell cycle control than we currently understand. The effect 
GWL knockdown has on the G1 and S phases in these experiments hints at a 
non-mitotic function of GWL, which has been suggested previously in the 




Chapter 4. Using a siRNA and drug library to screen for 




The observations described in the previous chapter raise the possibility that 
GWL depleted cancer cells display reduced proliferation rates not because of 
mitotic effects, but due to problems in S-phase. As previously discussed, these 
could be secondary effects, such as chromosome mis-segregation causing 
aneuploidy and cell stress. However, they could also reflect roles for GWL 
outside its canonical function as a mitotic kinase. Indeed, while work on this 
thesis was in progress, the Castro lab published a study suggesting that GWL 
dependent inhibition of PP2A-B55 could be important for S-phase progression 
via the stabilisation of Treslin (Charrasse et al. 2017). Treslin helps to regulate 
the initiation of DNA replication by promoting the pre-replication complex (pre-
RC) to the pre-initiation complex (pre-IC) by binding with Topoisomerase 
Binding Protein 1 (TOPBP1) in a CDK2-dependent process, and the presence 
of this complex is essential for loading of Cdc45L onto replication origins 
(Kumagai et al. 2010). This new information combined with the discovery that 
GWL may have a role in regulating the AKT pathway (Vera et al. 2015) 
suggests that looking for non-mitotic roles of GWL can prove productive. 
 
We decided to follow up the questions raised from Chapter 3 genetically and 
investigate synthetic lethal and synthetic resistant interactions of the kinase 
using both a siRNA depletion screen, and a small molecule drug screen. When 
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a synthetic lethal interaction exists between two genes, this means that the 
perturbation of either of these two particular genes individually is viable for the 
cell, but the disruption of both genes simultaneously causes loss of viability 
(Nagel et al. 2016; Beijersbergen et al. 2017). This is different to the idea of 
‘oncogene addiction’, in which a cancer cell is dependent on a particular 
oncogene or oncogenic pathway for survival, such as the RAS pathway 
(Weinstein 2002; S. V. Sharma & Settleman 2007). A summary of synthetic 
lethality and oncogene addiction can be seen in Figure 4.1. 
 
The class of drugs known as poly(ADP-ribose) polymerase (PARP) inhibitors 
are the first clinically approved drugs to be designed with synthetic lethality in 
mind (Lord & Ashworth 2017). Individuals with an inherited mutation in either 
the BRCA1 or BRCA2 gene are at a higher than average risk of developing 
breast or ovarian cancer (Miki et al. 1994; Wooster et al. 1995). Since the 
BRCA1 and BRCA2 proteins are required for homologous recombination during 
DNA repair and so are tumour suppressors, a loss of a functional copy 
increases the risk of genetic instability, a feature which is central to the 
development of all cancers (Venkitaraman 2002). It was found that BRCA1 and 
BRCA2 defective tumours are sensitive to PARP inhibitors, both in tumour 
models in vivo and in the clinic (Farmer et al. 2005; Evers et al. 2010; 
Rottenberg et al. 2008; Fong, P.C. et al. 2009) and to date three different 
PARP inhibitors have now been approved for the treatment of patients 
with BRCA-mutant ovarian cancer, and one for those with BRCA-mutant 
breast cancer. In addition, these agents have also shown promising results in 
patients with BRCA-mutant prostate cancer (Ashworth & Lord 2018). Overall, 
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the PARP-BRCA interaction provides the first example of a successful synthetic 
lethal approach that has reached the clinic.  
Technologies such as high-throughput siRNA and CRISPR-Cas9 screening 
which allow large-scale screening directly in human cell culture, as well as 
bioinformatics predictions in theory should speed up the search for cancer-
specific pathway alterations (Ashworth & Lord 2018). Such methods have 
identified many potential therapeutic targets but have also highlighted just how 
complex cancer cell signalling is, as cells in a tumour are heterogeneous in 
nature and exist in a complex microenvironment (O'Neil et al. 2017). Therefore, 
synthetic lethality candidates should be experimentally verified. This chapter will 
describe the results of the siRNA and drug screens that we carried out, thanks 
to our collaborator, Chris Lord at the Institute of Cancer Research (ICR).  
A total of 63 drugs were screened for synthetic sensitivity and resistance with 
GWL. MDA-MB-231 shScr and shGWL cells were treated either with 2 μg/mL 
DMSO vehicle control or with 2 μg/mL Dox for 72 hours to induce shRNA, 
followed by 24 hours drug treatment, and then the cell viability was assessed 
via MTT assay. A spreadsheet showing the raw data from this screen, including 
the drug names and concentrations used, is listed in Appendix 1. The majority 
of the analysis was carried out on the siRNA screen by the Lord laboratory, and 
so this will be the focus of this chapter. The siRNA screen is described in more 
detail in Section 4.2.   
Having a two-pronged approach as we have done here, screening for synthetic 
lethality candidates with both siRNA and a small molecule drug screen, means 
that more confidence can be had in hits that appear in both screening methods. 
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The sequential chapter will explore the experimental validation of one of the 
most convincing synthetic lethality candidates from the screens – CDK4/6. 
4.2 siRNA screen hits that exhibit synthetic sensitivity with Greatwall 
kinase depletion 
If the siRNA screen results are interpreted with caution and with experimental 
validation of the most interesting candidates, a synthetic lethality screen could 
provide us with much information on the cellular pathways that are affected by 
the loss of GWL that could be exploited therapeutically. We carried out an 
siRNA screen with MDA-MB-231 shScr and shGWL cells as shRNA control and 
to deplete GWL, respectively, against a siRNA library of 1535 proteins enriched 
for cancer-associated genes. To induce shRNA, 2 μg/mL Dox was added. In the 
wells where shRNA was not induced, cells were treated with 2 μg/mL DMSO 
vehicle control instead. The cells were treated with Dox (or DMSO) for 72 hours 
before addition of siRNA. siRNA induction was allowed for a further 48 hours, 
then cell viability was assessed via MTT assay. The results of the siRNA screen 
with GWL and Scr shRNA induction, shown as two technical repeats, can be 
seen in Figure 4.2. The viability of the GWL shRNA cells according to 
absorbance of MTT assay are on the y-axis, and the viability of the control Scr 
shRNA cells are on the x-axis of the graph. The closer a data point is to the 
bottom right corner of the graph, it means that the siRNA being tested had a 
greater, more adverse effect on the shGWL cell viability compared to the cells in 
which GWL was not also depleted. In both Fig 4.2 A) and B), the red dot in 



















Figure 4.1 The difference between oncogene addiction 
and synthetic lethality A) Oncogene addiction. Cancer cells 
that have an activating mutation in Gene A can become 
addicted to the proliferative signal encoded by this gene and 
so can be hypersensitive to treatments that inhibit the pathway 
activated by Gene A. B) Synthetic lethality. If Genes A and B 
are synthetic lethal, then this means that the inactivation of 
Gene B will be lethal to cancer cells with a mutation in Gene A 
but not to normal cells with a wild-type Gene A. Adapted from 





































Figure 4.2 Results from two independent siRNA screens using 
MDA-MB-231 shScr and shGWL cells A) and B) represent two 
biological replicates of the screen. The viability of the GWL shRNA 
cells are on the y-axis, and the viability of the Scr shRNA cells are 
on the x-axis. Data points that are over to the bottom right quarter 
of the graph means that the siRNA had a more adverse effect on 
the shGWLcells compared to the control. The red dot in each plot 
represents the siRNA against CDK4.
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Conversely, this also means that data points towards the top left corner of the 
graph means that a synthetic resistant effect was produced between the 
corresponding siRNA and GWL depletion. 
The data from the siRNA screen was also analysed by dividing the results into 
pools of either ‘synthetic resistant’ or ‘synthetic sensitive’ hits and plotting their 
corresponding Drug Effect scores. The Drug Effect is a statistical analysis of the 
data that does not evaluate how large the effect is, but rather how confident one 
can be that the observed effect is real. Drug Effect corrected is the Drug Effect 
of the shScr cell line subtracted from the shGWL cell line to get the net effect of 
GWL knockdown compared to the control. So, the larger the corrected Drug 
Effect, the more confidence in the effect there can be. The synthetic sensitive 
hits and their corresponding Drug Effect scores are plotted in Figure 4.3, and a 
table showing the protein functions of these synthetic sensitive hits is shown in 
Table 4.1. As shown in Table 4.1, the majority of the genes that show synthetic 
sensitivity with GWL are involved in DNA replication or repair, cell cycle control 
and proliferative signalling pathways including CDK4. The siCDK4 may not be 
the most lethal siRNA to use in combination with GWL depletion, but this result 
was consistent across the two replicates and was not very toxic to the control 
shScr cells (Fig. 4.2). It must also be noted that some negative control siRNA 
oligonucleotides appeared as synthetic sensitive hits in Fig. 4.3. This is why the 




















































Figure 4.3 Synthetic sensitive hits with GWL found in the siRNA 
screen Drug Effect is a statistical analysis of the data that does not evalu-
ate how large the effect is, but rather how confident one can be that the 
observed effect is real. Drug Effect corrected is the Drug Effect of the 
shScr cell line subtracted from the shGWL cell line to get the net effect of 
GWL knockdown compared to the control. So the more negative the 




Figure 4.4 Synthetic resistant hits with GWL found in the siRNA 
screen This data is plotted in the manner shown in Fig. 4.3, but with the 
hits that produced a survival effect. The Drug Effect is a statistical analysis 
of the data that does not evaluate how large the effect is, but rather how 
confident one can be that the observed effect is real. Drug Effect corrected 
is the Drug Effect of the shScr cell line subtracted from the shGWL cell line 
to get the net effect of GWL knockdown compared to the control. So the 
larger the corrected Drug Effect, the more confidence in the effect there 
can be.




























































4.3 siRNA screen hits that exhibit synthetic resistance with Greatwall 
kinase depletion 
In the same format as the synthetic sensitive results above, the synthetic 
resistant hits were also analysed. These genes, when simultaneously knocked 
down with GWL, exhibited an increase in cell viability compared to the Scr 
shRNA cells. The synthetic resistant hits and their corresponding Drug Effect 
scores are plotted in Figure 4.4, and a table showing the protein functions of 
these synthetic sensitive hits is shown in Table 4.2. Mirroring the results shown 
in Table 4.1, the majority of the genes that show synthetic resistance with GWL 
are also involved in DNA replication or repair, cell cycle control and proliferative 
signalling pathways (Table 4.2). Interestingly, the G1/S checkpoint protein 
CHEK1 is flagged as a synthetic resistant siRNA hit (Fig. 4.4 and Table 4.2). 
This makes sense, because if a cell with depleted GWL suffers DNA damage 
and chromosomal instability from a mismanaged mitosis caused by unrestricted 
PP2A-B55 phosphatase activity, then a simultaneous absence of CHEK1 could 
help push these cells through the DNA damage checkpoint during the 










Gene Name Protein Name Function
XRCC3 DNA Repair Protein XRCC3 Homologous recombination repair
MUS81 Crossover junction endonuclease MUS81 DNA repair, HR, meiosis
MYB MYB Proto-Oncogene, Transcription Factor Transcription regulator; oncogene
NUDT1 Nudix Hydrolase 1 Preventing incorporation of oxidized nucleoside triphosphates into DNA/RNA
PML Promyelocytic leukemia protein Formation of PML nuclear bodies; tumour suppressor
PLAG1 Pleiomorphic Adenoma Gene 1 Zinc Finger Transcription factor; overexpression increases cell proliferation
FANCI Fanconi Anemia Complementation Group I DNA repair
TAF1 TATA-Box Binding Protein Associated Factor 1 Part of a transcription factor complex
BRD4 Bromodomain Containing 4 Associates with acetylated chromatin; provides epigenetic memory for postmitotic G1 gene transcription
TJP2 Tight Junction Protein 2 Tight junctions
DKFZP761P0423 PEAK1 related, kinase-activating pseudokinase 1 Cell migration, motility and shape regulation
RABEP1 Rab GTPase-binding effector protein 1 Endocytic membrane fusion; membrane trafficking of recycling endosomes
TTBK1 Tau Tubulin Kinase 1 Regulates phosphorylation of tau protein, which associates with microtubule assemblies
CDKN2A Cyclin dependent kinase inhibitor 2A Cell cycle; p16 and p14 are gene products 
ATM Ataxia Telangiectasia Mutated kinase PI3/PI4-kinase family; cell cycle checkpoint
SRPK2 Serine/Arginine-Rich Protein-Specific Kinase 2 Upregulates cyclin D1 and cyclin A1 expression
PRKCZ Protein kinase C zeta type PKC family; cell proliferation pathways
CDK4 Cyclin dependent kinase 4 Cell cycle G1 phase progression; phosphorylates Rb
MAP2K4 mitogen-activated protein kinase kinase 4 MAPK and SAP/JNK pathways
MAP3K8 Mitogen-Activated Protein Kinase Kinase Kinase 8 Cytoplasm; can activate MAP kinase and JNK kinase pathways
ACVR2 Activin A Receptor Type 2A Mediates the functions of activins, part of the transforming growth factor-beta (TGF-beta) superfamily
MAP3K7IP1 Mitogen-activated protein kinase kinase kinase 7-interacting protein 1 Regulator of the MAP kinase kinase kinase MAP3K7/TAK1
PI4K2B Phosphatidylinositol 4-Kinase Type 2 Beta Contributes to overall PI4-kinase activity; metabolism
PIK3C2A Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Alpha Part of the phosphoinositide 3-kinase (PI3K) family
PRKG2 Protein kinase cGMP-dependent 2 Binds to and inhibits several Tyrosine Kinase Receptors
IKBKB Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta NF-kappa-B pathway
TNFAIP3 Tumor Necrosis Factor Alpha Induced Protein 3 ubiquitin ligase and deubiquitinase activities; inflammation
PRKR Protein kinase R/eukaryotic translation initiation factor 2-alpha kinase 2 Immune response to viruses
CRLF2 Cytokine Receptor Like Factor 2 Type I cytokine receptor family; activate STAT3, STAT5, and JAK2 pathways
AATK Apoptosis Associated Tyrosine Kinase Induced during apoptosis
CARKL Sedoheptulokinase Glucose metabolism
PDK2 Pyruvate dehydrogenase kinase 2 Increases conversion of pyruvate to lactate in cytosol
INSR Insulin receptor Insulin signalling pathway; glucose and carbohydrate metabolism
PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 Glucose metabolism and cell cycle progression; Cdk1 regulator
DGKG Diacylglycerol Kinase Gamma Lipid metabolism; possibly cell cycle regulation
C2orf44 WD Repeat And Coiled Coil Containing Uncharacterised
DUSP21 Dual specificity phosphatase 21 Found in cytoplasm and nucleus
DNA repair, gene expression, 
nuclear localisation








Table 4.1 A summary of the functions of the synthetic sensitive hits of the siRNA screen Each gene found as a synthetic 
sensitive hit in the siRNA screen alongside GWL depletion has next to it it’s full protein name and a brief description of its function. 




Gene Name Protein Name Function
KIAA1765 Serine/threonine-protein kinase DCLK3 Nuclear Ser/Thr kinase
RPA3 Replication protein A 14 kDa subunit DNA replication and DDR
ZNF331 Zinc finger protein 331 Transcriptional regulation
CLK3 Dual specificity protein kinase CLK3 Spliceosome
TBL1XR1 Transducin beta like 1 X-linked receptor 1 Transcriptional regulation
SETBP1 SET binding protein 1 DNA replication
KMT2D Lysine-specific methyltransferase 2D Histone methyltransferase
EXOSC10 Exosome component 10 RNA processing and degradation
HRPT2 Cell Division Cycle 73 Transcriptional and post-transcriptional regulation
POLK DNA polymerase kappa Translesion DNA synthesis
HOXA9 Homeobox protein A9 Transcription factor
MGC4796 Serine/threonine kinase 40 Regulates NF-k-B and p53-mediated transcription
DDIT3 DNA Damage Inducible Transcript 3 Transcription factor
SSX1 SSX family member 1 Transcriptional regulation
RBM15 RNA binding protein 15 RNA methylation
PAK7 or PAK5 p21 (RAC1) activated kinase 5 Cytoskeleton and cell proliferation
KALRN Kalirin Cytoskeleton
PRKWNK1 WNK lysine deficient protein kinase 1 Sodium and choloride ion transport
ICK Intestinal cell kinase Ciliogenesis; intestinal epithelia proliferation
ARK5 NUAK family SNF1-like kinase 1 Cell adhesion, senescence, cell proliferation
CLTC Clathrin heavy chain 1 Intracellular transport
EPHB6 Ephrin type-B receptor 6 Cell adhesion and migration
PCTK1 Cyclin dependent kinase 16 Intracellular transport; exocytosis
CALM2 Calmodulin 2 Centrosome cycle; cytokinesis
CYLD CYLD Lysine 63 Deubiquitinase Cytoskeleton
ARHGAP26 Rho GTPase activating protein 26 Extracellular matrix; cytoskeleton
DNM2 Dynamin 2 Endocytosis; cytoskeleton
CKS2 CDC28 protein kinase regulatory subunit 2 Cell cycle; binds to Cdks
PLK3 Polo-like kinase 3 Cell cycle; cell stress response
STK38L Serine/threonine-protein kinase 38-like Cell cycle; apoptosis
CCND2 Cyclin D2 Cell cycle; binds to Cdk4 or Cdk6
CHEK1 Checkpoint kinase 1 Checkpoint mediated cell cycle arrest
STK16 Serine/threonine-protein kinase 16 Cell membrane associated kinase
ADRBK2 G protein-coupled receptor kinase Cell signalling
DYRK4 Dual Specificity Tyrosine Phosphorylation Regulated Kinase 4 Cell differentiation and proliferation
BMX BMX non-receptor tyrosine kinase Cell proliferation
CDKL5 Cyclin-dependent kinase-like 5 Nerve cell growth, division and migration
MYLK2 Myosin light chain kinase 2 Skeletal muscle specific
FGFR3 Fibroblast growth factor receptor 3 Bone development and maintenance
GRK1 G protein-coupled receptor kinase 1/Rhodopsin kinase Phototransduction
STK22D Testis specific serine kinase 1B Spermiogenesis
SGK Serum/Glucocorticoid Regulated Kinase 1 Cell stress response; ion transport
TNFRSF17 Tumour Necrosis Factor receptor superfamily member 17 B-cell development; autoimmune response
MAP4K5 Mitogen-activated protein kinase kinase kinase kinase 5 Cellular stress response
IKBKAP Elongator Complex Protein 1 Proinflammatory signalling
NDRG1 Protein NDRG1 Cellular stress response
THNSL1 Threonine synthase-like 1 Binds pyridoxal phosphate


















Table 4.2 A summary of the functions of the synthetic resistant hits of 
the siRNA screen Each gene found as a synthetic resistant hit in the siRNA 
screen alongside GWL depletion has next to it it’s full protein name and a 
brief description of its function. These hits were then categorised into broad 
themes according to their function within the cell, and tabulated together.
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4.4 Gene Ontology analysis to look for gene category statistical 
overrepresentation  
The next question to ask is if the lists of synthetic sensitive and resistant 
candidate genes obtained from the siRNA screen are all there by chance, or if 
there is overrepresentation or enrichment for particular categories of genes 
according to their roles in the cell. An analysis was run on these two sets of hits 
using the PANTHER Gene List Analysis tool (Mi et al. 2013) 









































2.8 4.64 0.00000177 1.657142857 
Table 4.3 Statistical Overrepresentation outputs of the synthetic sensitive 










































3.49 4.88 0.00000002 1.398280802 
Table 4.4 Statistical Overrepresentation outputs of the synthetic resistant 
hits from the siRNA screen 
 
The output from the analysis gives an ‘expected’ value for how many genes 
from particular categories should appear at random, as well as the ‘fold 
enrichment’. To normalise the data, I divided the enriched value by the 
expected value, and the results of the synthetic sensitivity overrepresentation 
test are shown in Table 4.3 and those for the synthetic resistant hits are shown 
in Table 4.4. Whilst the analysis gives some very generic gene categories that 
are not that informative, in both lists of hits they were found to be significantly 
enriched for genes involved in cell cycle control. Graphs summarising the 
enrichment folds of the categories of genes in the hit lists according to the 






































































































Figure 4.5 Normalised fold enrichment of the gene classification 
hits from the PANTHER GO Statistical Overrepresentation test A 
graphical summary of the data shown in Tables 4.1 and 4.2. A) Gene 
classifications that are overrepresented in the synthetic sensitive hits B) 




These graphs show how many more times cell cycle proteins appear as 
synthetic sensitive or resistant hits in the siRNA screen with GWL depletion.  
 
4.5 Conclusions and discussion 
It is important to bear in mind that siRNA screens, like all other screening 
approaches, are susceptible to false positives with one of the most important 
being off-target effects (OTEs) (Echeverri et al. 2006; Sigoillot & King 2011). 
With this in mind, the Lord lab performed a parallel screen with GWL shRNA 
MDA-MB-231 cells and a panel of drugs targeting proteins known to be 
important for cancer cell signalling. The CDK4/6 inhibitor Palbociclib was a hit in 
this drug screen as well as siCDK4 in the siRNA screen. A bioinformatics 
analysis of the siRNA screen hits found that they were significantly enriched for 
cell cycle genes, which strengthens the case for any hits that are involved in the 
cell cycle, as this means it is highly likely they have not appeared as hits by 
chance or as false positives. Thus, CDK4 was chosen as the most interesting 
candidate for further validation and investigation because this is a novel finding, 
pertains to the interesting links explained earlier regarding the non-mitotic 
functions of GWL (Charrasse et al. 2017), and there are already successful 




Chapter 5. Confirming the synthetic sensitivity of Greatwall 
kinase and CDK4 
5.1 Introduction 
The observations described in the previous chapter raise the possibility that 
GWL depleted cancer cells display reduced proliferation rates not because of 
mitotic effects, but due to problems in S phase. As discussed previously, these 
could be due to earlier chromosome mis-segregation causing aneuploidy and 
stress. However, they could also reflect roles for GWL outside its canonical 
function as a mitotic kinase. Indeed, while work on this thesis was in progress 
the Castro lab published a study suggesting that GWL dependent inhibition of 
PP2A-B55 could be important for S phase progression via the stabilisation of 
Treslin, an important member of the complex that is associated with the 
replication fork (Charrasse et al. 2017).  
 
We decided to follow this question up genetically and investigate synthetic 
sensitive interactions of the kinase using a siRNA depletion and small molecule 
drug screen, which was discussed in Chapter 4. This chapter will explore the 
experimental validation of one of the most convincing synthetic sensitive 
candidates from the screens – CDK4. 
 
5.2 Confirming the synthetic sensitivity between Greatwall kinase and 
CDK4 
One of the most convincing and interesting synthetic sensitive results from this 
screen was CDK4. We were especially confident in this result because CDK4 
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was identified as a hit in both the siRNA and drug screens. Both the biological 
implications and the therapeutic potential of this genetic interaction warranted 
further efforts to explore this finding further. From a mechanistic point of view 
this is an intriguing result because CDK4 is active in G1/S phase, in contrast to 
GWL’s peak activity in mitotic entry. This suggests a novel, additional role for 
GWL outside of mitosis. Secondly, the CDK4/6 inhibitors Palbociclib 
(IBRANCE®) and Ribociclib (Kisqali®) are in clinical use for breast cancer 
patients in the UK and US (Iacobucci 2017; Kmietowicz 2017; Finn et al. 2016; 
Hortobagyi et al. 2016), therefore any synergy between GWL and CDK4/6 will 
be clinically relevant. As mentioned in Chapter 1 – Introduction, certain types 
of TNBC cell have been shown to be resistant to CDK4/6 inhibition (Asghar et 
al. 2017) but also a synergistic reaction between PI3K and CDK4/6 inhibitors 
exists in PIK3CA-mutant cells. There is an on-going therapeutic trial that is 
assessing the effectiveness of CDK4/6 inhibition in combination with PI3K 
inhibition, in patients with PIK3CA-mutant TNBC (Asghar et al. 2017). This 
opens up the possibility of using CDK4/6 inhibitors in certain types of TNBC 
cells when there is a synergistic relationship between CDK4/6 and another 
protein, as well as a biomarker to indicate this sensitivity. This makes the 
discovery of a kind of synergy between GWL and CDK4/6 particularly exciting, 
as this could have clinical relevance. Figure 5.1 shows the summary of the 
results from the siRNA and drug screens that highlighted CDK4 as a hit. In both 
screens, targeting CDK4 with siRNA (Fig. 5.1A) or Palbociclib (Fig. 5.1B) 





















































Figure 5.1 Summary of high-throughput siRNA and drug screens that 
identified CDK4 as a synthetic lethality hit with GWL Scr and GWL 
shRNA MDA-MB-231 cell lines were tested with either a DMSO control or 
Dox treatment, and with or without an additional siRNA or an anti-cancer 
drug. Each treatment was carried out with three technical replicates (three 
96-well plate wells) and then the entire experiment was carried out a second 
time to give a total of two biological replicates. The plotted Z-scores as a 
measure of cell viability by MTT assay, are the mean of the two repeats. A) 
with Cdk4 siRNA B) with 1000 nM Cdk4/6 inhibitor Palbociclib.
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In pharmacology the terms synergistic and additive have distinct, precise 
definitions. Synergy is the interaction of biological structures or substances that 
together, produce an overall effect that is greater than the sum of the individual 
effects. An additive effect is when two substances used in combination produce 
a total effect that is the same as the sum of the individual effects. In the 
remaining Results chapters – Chapters 5 and 6, I refer to the effects seen 
when both GWL and CDK4 are inhibited as either a ‘synergy’, ‘synthetic lethal’ 
or ‘synthetic sensitive’ effect. Whilst clear deleterious effects on cell viability and 
the cell cycle profiles can be seen in these treated cells, I cannot say for certain 
at this stage that it is truly a synergistic relationship as defined in the 
pharmacological literature (Foucquier & Guedj 2015; Chou 2006). This is 
expanded upon further in the Chapter 7 discussion.  
 
5.3 Using siRNA and small molecule libraries to screen for synthetic 
sensitivity in MDA-MB-231 Greatwall shRNA cells 
The next step was to validate this synergy experimentally. Reflecting the 
structure of Chapter 3, I started by analysing the effect of depleting both GWL 
and CDK4/6 with colony formation assays. I carried out colony formation assays 
in MDA-MB-231 shGWL cells with a range of concentrations of Ribociclib (also 
known as Lee011 by the supplier, so Ribociclib is labelled as Lee011 in figures) 
(Figure 5.2) and Palbociclib (Figure 5.3), with and without Dox. As shown by 
Figs 5.2 and 5.3, the synthetic sensitivity between GWL and CDK4 appears to 
be present in these cells. I wanted to find a concentration of the CDK4/6 
inhibitors that wouldn’t significantly affect the cell viability when used alone but 




+ 0.5 μM + 0.5 μM + Dox
+ 0.25 μM + 0.25 μM + Dox
+ 1 μM + 1 μM + Dox
+ 2 μM + 2 μM + Dox
Figure 5.2 A range of Ribociclib/Lee011 doses to determine optimal syn-
thetic lethality with GWL 20,000 MDA-MB-231 shGWL cells were plated 
onto 10 cm dishes, treated with the indicated treatments and allowed to grow 










50 nM 50 nM + Dox
75 nM 75 nM + Dox
100 nM 100 nM + Dox
150 nM 150 nM + Dox
Figure 5.3 A range of Palbociclib doses to determine optimal synthet-
ic lethality with GWL 20,000 MDA-MB-231 shGwl cells were plated onto 
10 cm dishes, treated with the indicated treatments and allowed to grow for 







A) No treatment control B) +Dox 
MDA-MB-231 HS578T
E) No treatment control F) +Dox 
G) +0.5μM Lee011 H) +Dox ; +0.5μM Lee011
MDA-MB-436
I) No treatment control J) +Dox 
K) +0.5μM Lee011 L) +Dox ; +0.5μM Lee011
MCF10a
M) No treatment control N) +Dox 
O) +0.5μM Lee011 P) +Dox ; +0.5μM Lee011
C) +0.5μM Lee011 D) +Dox ; +0.5μM Lee011
Figure 5.4 The sensitivity of a panel of breast cell lines to simultaneous 
GWL depletion and CDK4/6 inhibition Representative images of this experi-
ment: 20,000 live cells were plated onto each 10 cm dish, the appropriate 
treatment added and grown for 7-8 days prior to staining with 0.05% Crystal 
Violet solution. N=3
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I found that 0.5 μM Ribociclib/Lee011 and 50 nM Palbociclib were the best 
concentrations to achieve this effect, so an additional set of colony assay 
experiments was carried out using Ribociclib/Lee011 at 0.5 μM using four cell 
lines (MDA-MB-231, HS578T, MDA-MB-436 and MCF10a). The results are 
shown in Figure 5.4. Each experiment was carried out three separate times and 
the plates photographed, but the colonies were not counted. These colony 
assays look different to those in Chapter 3 because instead of using a feeder 
layer, plating 1000 cells and growing the cells over the course of two weeks; the 
plates in Fig. 5.4 were plated with 20,000 cells and grown for 7-8 days. 
 
It is clear that the MDA-MB-231 and HS578T cells (Fig. 5.4A to H) are very 
sensitive to the simultaneous depletion of GWL and inhibition of CDK4/6. The 
MDA-MB-436 cells, like with the just GWL knockdown treatment described in 
Chapter 3, are not sensitive to GWL knockdown nor the double treatment of 
GWL depletion and CDK4/6 inhibition.  
 
The 436 cells also show no sensitivity to the 0.5 μM dose of Ribociclib/Lee011 
(Fig. 5.4K), when the other three cell lines show a degree of sensitivity to this 
treatment. It is logical that MDA-MB-436 cells are resistant to CDK4/6 inhibition 
because, unlike MDA-MB-231 and HS578T cells, they lack the Retinoblastoma 
(Rb) protein (Robinson et al. 2013). The MCF10a cells also show GWL and 
CDK4/6 synthetic lethality, and are the most sensitive to the single 
Ribociclib/Lee011 treatment out of the cell lines tested (Fig 5.4M to P), while 
MDA-MB-231 and HS578T display resistance to CDK4/6 inhibition, which is 
typical of many TNBC cells (Asghar et al. 2017).  
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A) No treatment control B) +Dox
C) +50 nm Palbobicin D) +Dox; +50 nm Palbobicin
MDA-MB-231 shGWL
Figure 5.5 Treatment with the CDK4/6 inhibitor Palbociclib shows 
synthetic lethality with GWL knockdown in MDA-MB-231 cells 
20,000 live cells were plated onto each 10 cm dish, the appropriate 
treatment added and grown for 7-8 days prior to staining with 0.05% 
Crystal Violet solution. Represenative images of N=3.
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I then tested the GWL-CDK4 synergy once more using the other clinically 
approved CDK4/6 inhibitor – Palbociclib. Figure 5.5 shows that whilst 
Palbociclib seems to be more effective than Ribociclib/Lee011 on MDA-MB-231 
cells because of the lower doses used, the synergistic effect between CDK4/6 
inhibition and GWL knockdown is still apparent at 50 nM. 
 
Recurring problems when using RNAi technologies are off-target effects. So far, 
all results have been produced with a single shRNA and could be due to the 
depletion of other factors rather than loss of GWL. To check that the effect of 
GWL knockdown on cell proliferation as well as the GWL-CDK4 synergy are 
reliable and not a product of shRNA off-target effects, I replicated the colony 
assay experiment shown in Fig 5.4 but with Dox-inducible CRISPR-GWL MDA-
MB-231 cells, and a Scr control (Álvarez-Fernández, Sanz-Flores, Sanz-
Castillo, Salazar-Roa, Partida, Zapatero-Solana, Ali, Manchado, Lowe, 
VanArsdale, Shields, Caldas, Quintela-Fandino & Malumbres 2018b). These 
cell lines were generously gifted from Marcos Malumbres and have also been 
published in the following study (Álvarez-Fernández, Sanz-Flores, Sanz-
Castillo, Salazar-Roa, Partida, Zapatero-Solana, Ali, Manchado, Lowe, 
VanArsdale, Shields, Caldas, Quintela-Fandino & Malumbres 2018b). The 
immunoblot to verify the GWL knockdown in this inducible CRISPR-GWL line is 
shown in Figure 5.6. The results of the colony assays to verify the reliability of 
the GWL knockdown phenotype and the GWL-CDK4 synthetic lethality are 















- dox + dox
Figure 5.6 Immunoblot to verify the Greatwall kinase knockout using 
the MDA-MB-231 inducible CRISPR-Cas9 GWL cell line The stable and 
reversible CRISPR mechanism was induced by adding 2 μg/mL Doxycycline 
and incubating cells for 5 days before harvesting cell lysate. GWL expression 
levels were detected using an anti-MASTL antibody, and an anti-α-Tubulin 
antibody was used as a loading control.
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A) No treatment control B) +Dox 
C) +0.5μM Lee011 D) +Dox ; +0.5μM Lee011
CRISPRi Scramble
E) No treatment control F) +Dox 
G) +0.5μM Lee011 H) +Dox ; +0.5μM Lee011
CRISPRi Gwl
Figure 5.7 Confirming synergy between GWL and CDK4 using an 
inducible CRISPR-Cas9 MDA-MB-231 cell line 20,000 live cells were 
plated onto each 10 cm dish, the appropriate treatment added and 
grown for 7-8 days prior to staining with 0.05 % Crystal Violet solution. 
N=2.
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Similar to the shRNA depletion, the induced GWL knockout causes a significant 
reduction in colony formation to these Cas9 expressing MDA-MB-231 cells (Fig. 
5.7F), and these cell lines are also sensitive to just the CDK4/6 inhibition 
treatment alone (Fig 5.7C and G). However, there is a clear synergistic effect 
when both GWL and CDK4/6 are targeted that almost completely wipes out 
colonies. This effect is specific for the GWL gRNA and does not occur in the 
control CRISPR-Scr line (Fig 5.7D and H). 
 
5.4 The synergy between Greatwall kinase and CDK4 results in a depletion 
of S phase cells  
In order to further characterise the synergy between GWL and CDK4, I 
evaluated the effect of the double treatment of GWL knockdown and CDK4/6 
inhibition on the cell cycle phase populations using pulse EdU labelling and 
Propium Iodide (PI) staining followed by FACS analysis. A representative 
example of a set of FACS plots for this experiment is shown in Figure 5.8A. 
Using the BD CSampler™ Analysis Software, values for how many cells are in 
which cell cycle stage can be obtained by gating around the appropriate 
sections of the plots. However, for a range of reasons including sub-G1 cells, 
polyploidy cells, and cell fragments, not every cell that passes through the 
FACS analysis falls neatly into G1, S or G2/M phase. This means the 
percentages of the cell cycle stages do not add up to 100%, and thus would 



















































i) Ctrl ii) + Dox
iii) + 0.5 μM Lee011 iv) + Dox; + 0.5 μM Lee011
Figure 5.8 Simultaneous knockdown of GWL and CDK4/6 inhibition 
causes a dramatic loss in the S-phase cell population MDA-MB-231 
shGWL cells treated with 2 μM Dox for 5 days. In the final 24 hours, some cells 
were also treated with 0.5 μM Ribociclib/Lee011. A) Representative FACS plot 
B) Means of N=4 experiments normalised. Unpaired t-test used to compare 
individual conditions to the NT control group.
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To normalise this data, the total of the gated percentages of G1, S and G2/M 
cells became the new ‘100%’. Then, each gated percentage of each cell cycle 
phase was normalised to this value. This normalised data is plotted in Figure 
5.8B. GWL depletion causes a mild increase in the G2 population, while both 
CDK4 inhibition and GWL depletion causes a mild decrease of S phase cells 
and increase in G1 population. Strikingly, after double treatment (ie CDK4 
inhibition and GWL depletion) the S phase population drops by a further 50% 
compared to the single treatments resulting in less than 10 % of the overall cell 
population. Using the GraphPad Prism software, I performed unpaired t-tests 
comparing the S phase population of each treatment against the S phase 
population of the double treatment + Dox + Lee011 condition. All three of these 
tests showed p < 0.001 which is represented by the three stars on the graph in 
Fig. 5.8 B.  
	
To further analyse the differences between the S phase populations compared 
to the control, I used the Shared Control function in the Estimation Statistics tool 
to analyse just the different S phase counts (Ho et al. 2018). The results of this 
analysis are shown in Figure 5.9. This method of plotting the data allows for the 
mean differences and their confidence intervals to be easily compared. 
Because there are multiple groups or treatments in this experiment, the side-by-
side plotting allows the visual comparison of effect sizes. The bold, vertical line 
representing the 95% Confidence Interval of the + Dox and + Lee011 treatment 






Figure 5.9 Shared Control analysis to evaluate the differences in S-phase 
populations in MDA-MB-231 shGWL cells treated with GWL knockdown 
and CDK4/6 inhibitor Using the Estimation Statistics tool (Ho et al. 2018) a 
swarm plot of just the S-phase populations from the data shown in Fig. 5.8B.   
% S phase 
population
Δ % S phase 
population
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The experiment shown in Fig. 5.8 was repeated, but with MDA-MB-436 cells 
and Ribociclib/Lee011, MDA-MB-231 inducible CRISPR-GWL cells and 
Ribociclib/Lee011, and finally with MDA-MB-231 shGWL cell and Palbobicin. 
The data of the MDA-MB-436 experiment is shown in Figure 5.10, where again 
a representative set of FACS plots (Fig. 5.10A) is shown as well as the 
normalised data across the biological replicates (Fig. 5.10B). Not only do the 
individual treatments of either GWL knockdown or CDK4/6 inhibition not have 
any noticeable effect on the cell cycle populations, but the double treatment 
also shows no significant effect. This experiment was repeated three times so 
the S phase populations between the non-treatment control group and the + 
Dox; + Lee011 group were tested with an unpaired t-test in GraphPad Prism 
and no significant difference was found. 
 
This experiment format was repeated again but instead using the inducible 
CRISPR-GWL MDA-MB-231 cell line. This data is shown in Figure 5.11 and the 
experiment was repeated only twice so this result lacks statistical analysis. The 
same effect is seen, with the S phase population decreasing in the condition of 
the double treatment, however the SEM error bars on the boundaries of the G1 
and the S phase cells are large. The G2/M population of this set of cells in the + 
Dox; + Ribociclib/Lee011 group has also increased more compared to that seen 
in the shGWL cells in Fig. 5.8. Ideally this experiment needs more biological 
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Figure 5.10 MDA-MB-436 cells are resistant to simultaneous knock-
down of Greatwall kinase and CDK4/6 inhibition MDA-MB-436 shGWL-
cells treated with 2 μM Dox for 5 days. In the final 24 hours, some cells were 
also treated with 0.5 μM Ribociclib/Lee011. A) Representative FACS plot B) 
Means of N=3 experiments normalised. Unpaired t-test used to compare 
individual conditions to the NT control group.
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i) Ctrl ii) + Dox iii) + 0.5 μM Lee011














































Figure 5.11 MDA-MB-231 CRISPR-GWL cells are sensitive to simultane-
ous knockdown of Greatwall kinase and CDK4/6 inhibition MDA-MB-231 
CRISPR-GWL cells treated with 2 μM Dox for 5 days. In the final 24 hours, 
some cells were also treated with 0.5 μM Ribociclib/Lee011. A) Representative 
FACS plot B) Means of N=2 experiments normalised. 
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In addition, the experiment shown in Fig. 5.8 with the shGWL MDA-MB-231 
cells was repeated but this time with 50 nM Palbociclib used as the method of 
CDK4/6 inhibition. This data is shown in Figure 5.12, and also this experiment 
was repeated twice so lacks statistical analysis. The data here is however 
consistent across the two samples so the error bars are very small. 50 nM 
Palbobicin treatment alone is quite deleterious to these cells, and the S phase 
population shrinks dramatically and the G1 population increases. However, in 
the double treatment including GWL knockdown, the S phase population 
decreases further slightly. 
 
To further investigate the fate of MDA-MB-231 cells lacking both GWL and 
CDK/6 activity, we used live cell imaging. MDA-MB-231 shGWL cells were 
seeded onto a 2-chamber imaging plate, 48 hours prior to commencement of 
imaging. One chamber had just 0.5 μM Ribociclib/Lee011 added to it five hours 
before imaging began. The second chamber of cells received this treatment too 
plus the 2 μg/mL Dox dose immediately after seeding, so these cells had 48 
hours of Dox exposure before imaging began. When analysing the resulting 
movies, one daughter cell from each division was tracked. If no further divisions 
are indicated following mitosis, then this means that neither daughter cell 
underwent a subsequent division. Moreover, this method allows us to 
determine, if the double treatment causes depletion cells by cell death, or 
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Figure 5.12 CDK4/6 inhibitor Palbociclib has a synergistic effect with 
GWL knockdown in MDA-MB-231 shGWL cells MDA-MB-231 shGWL cells 
treated with 2 μM Dox for 5 days. In the final 24 hours, some cells were also 










































Figure 5.13 Treating MDA-MB-231 shGWL cells with both CDK4/6i and 
GWL knockdown inhibits cell proliferation Cells were plated onto a 2-well 
imaging chamber 48 hours prior to filming. A) On day of filming, cells treated 
with 0.5 μM Lee011/Ribociclib only B) Cells treated with 2 μM Dox at time of 
plating 48 hours before filming and 0.5 μM Lee011/Ribociclib on day of filming. 
The horizontal red lines represent how long the cells stay in a rounded, mitotic 




In Fig. 5.13A the 0.5 μM dose of CDK4/6 inhibitor Ribociclib/Lee011 the 
observed cells all divided twice or three times during imaging. In the cells that 
received both Dox and Lee011 treatments, in Fig. 5.13B, there is a reduction in 
cell proliferation compared to the singular Lee011 treatment. In the cells treated 
with both Dox and Lee011, seven out of the ten cells tracked only completed 
one round of mitosis, including one that failed to exit after entering mitosis. 
These cells were approaching full shRNA-mediated GWL knockdown during 
filming in addition to the CDK4/6 treatment. However, this result mirrors the one 
seen in Fig. 3.9, which was filming the cells with just GWL knockdown 
treatment so no new information pertaining to the mechanism of the effect of 
the CDK4/6 inhibition in combination with GWL knockdown is gained here. This 
result suggests that when certain breast cancer cells with depleted GWL either 
exit the cell cycle, undergo arrest in G1 phase, or enter a G1-like state, rather 
than dying due to a programmed cell death pathway. However, this experiment 
would be much improved with a no treatment control to compare with the effect 
of the single CDK4/6 inhibitor treatment. Looking at Fig. 5.13A alone, without 
the no treatment control for this experiment it isn’t known if just the CDK4/6 
inhibitor perturbs the cell cycle. Further investigation into the possible 
mechanism behind the GWL and CDK4 synergy will be explored in the next 
chapter. 
 
5.5 Conclusions and discussion  
The work done in this chapter has verified that targeting GWL and CDK4 
simultaneously causes synthetic lethality in the Triple Negative breast cancer 
cell line MDA-MB-231. When looking at Figs. 5.8, 5.11, and 5.12, these results 
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clearly demonstrate that there is a genetic relationship between G1 kinase 
CDK4 and mitotic kinase GWL that is causing an increase in G1 cells and a 
reduction in S phase cells to occur. It was also found that using a different 
method of GWL knockdown, with the inducible CRISPR-GWL cell line, 
replicated the results of the shRNA induced GWL knockdown method: showing 
both growth inhibition in MDA-MB-231 cells, as well as synthetic lethality when 
combining GWL depletion with CDK4 inhibition. Combining the results from the 
live cell imaging experiments and the FACS analysis suggest that the cells are 
indeed arresting in G1 or exiting the cell cycle following co-depletion of both 
kinases. Intriguingly, GWL depletion alone already delays interphase 
progression in these cells (see Fig 3.8) and reduces the S phase population, 
but these effects are greatly exacerbated by simultaneous CDK4 inhibition. It is 
important to note that the synthetic lethal phenotype is not seen in the RB 
negative cell line MDA-MB-436. 
 
Taken together, these findings point to a novel role of GWL in early G1. This 
could be the result of GWL/ENSA depletion on Treslin that was recently 
described by Anna Castro and colleagues (Charrasse et al. 2017). If this were 
the case, however, we would not expect to see such specific phenotypes of 
GWL depletion on RB wild-type (WT) cells (MDA-MB-231), and no effects in the 
RB mutated cell line (MDA-MB-436). Taken together this suggest that the 
synergy between CDK4 and GWL does, indeed, occur at the level of RB 
inhibition, but further work comparing larger panels of cell lines will be 
necessary to substantiate this claim. 
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What the experiments in this chapter have not been able to fully quantify is the 
difference between the G1 phase cells that are still actively progressing through 
the cell cycle, and the G1 phase cells that are arrested in this phase. Some 
experiments with some G1 specific markers may help to clarify this. For 
example, time course immunoblots tracking the cell cycle status of the culture 
over several days and blotting for multiple G1 arrest markers such as Cdt1, p53, 
p21, p27 and p16. Since cell cycle pathways are often perturbed in cancerous 
cells it would be better to analyse a range of markers in order to make an 
informed observation. In addition, the fluorescent marker mVenus p27K− is able 
to label quiescent cells so this experiment could be done via IF microscopy 
(Oki et al. 2014). 
 
In conclusion, the data in this chapter has validated the synthetic lethality 
identified in the screen carried out by our collaborators in the ICR and 
strengthens the rationale for the theory that GWL is linked to other phases of 
the cell cycle (Charrasse et al. 2017; Peng et al. 2010). To our knowledge, the 
observation that knocking down GWL as well as inhibition of CDK4/6 
significantly reduces the S phase population whilst increasing the G1 phase 
population is original to this thesis.  
 
Our discovery of synthetic lethality between GWL and CDK4 is relevant for 
both clinical and basic research purposes. Not only could this synthetic 
lethality be potentially beneficial from a treatment regimen standpoint, but 
also with further research could lead to the discovery of non-mitotic roles of 
GWL which would increase our understanding of cell cycle control. 
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The next step in this project is to try to elucidate the mechanism of this novel 
phenotype. The active cyclin D-CDK4 complex is able to add an inhibitory 
phosphorylation to the RB protein. This relieves the RB-mediated inhibition of 
the transcription factor E2F, which commits the cell to progression into S phase 
and through the cell cycle. It has been found that inhibition of CDK4 is sufficient 
to induce senescence (Lessard et al. 2018), so it makes sense that inhibition of 
RB phosphorylation via CDK4/6 inhibition in combination with knockdown of 
pro-mitotic GWL decreases cell proliferation. It is also known that the 
downstream target of GWL, the phosphatase PP2A-B55, is a tumour 
suppressor that is often mutated or inactivated in cancer, including breast 
tumours (Álvarez-Fernández, Sanz-Flores, Sanz-Castillo, Salazar-Roa, Partida, 
Zapatero-Solana, Ali, Manchado, Lowe, VanArsdale, Shields, Caldas, Quintela-
Fandino & Malumbres 2018b; Perrotti & Neviani 2013; Janssens et al. 2005). It 
is possible that PP2A-B55 could also be responsible for inhibiting the activation 
of CDK7/CAK, CDK4 and/or inhibiting the phosphorylation of Rb. So, with 
PP2A-B55 being a known tumour suppressor, it could be the case that, in the 
context of a cancer cell with a high DNA damage load, GWL can act as a 
suppressor of the tumour suppressor PP2A-B55, thus linking GWL to CDK4 via 







Chapter 6. Investigation into the mechanism of the synergy 
between Greatwall kinase and CDK4 
6.1 Introduction 
In this chapter I report results that were inspired by the findings of the previous 
chapters (Chapters 4 and 5), which found a synergistic relationship between 
GWL and CDK4 in TNBC cells. The next logical step is to work out a 
mechanism for this relationship. In this chapter I enquire whether the synergy is 
dependent on either the downstream target of GWL, the phosphatase PP2A-
B55 or two of GWL’s currently known substrates and inhibitors of PP2A-B55: 
ENSA and ARPP19.  
 
The major function of GWL is the inhibition of PP2A-B55 during mitosis. 
Likewise, GWL inactivation in telophase is required for the re-activation of 
PP2A–B55α and δ complexes during mitotic exit (Manchado et al. 2010; 
Hégarat et al. 2014; Mochida et al. 2009; Castilho et al. 2009). If GWL is 
knocked down, then this means PP2A-B55 remains active throughout mitosis. 
Premature PP2A-B55 activity in GWL depleted cells could be linked to the G1/S 
transition by dephosphorylating RB, Cdc25 and/or dephosphorylating a CAK of 
CDK4, and thus inhibiting a cell from progressing past G1-phase. It is already 
known that PP2A-B55 dephosphorylates and inactivates Cdc25 at mitotic exit 
(Mochida et al. 2009; Forester et al. 2007; E. S. Johnson & Kornbluth 2012), but 
the role of Cdc25 in G1 phase is not well established. It has been proposed that 
a different subunit of the PP2A holoenzyme family, PP2A-B” also known as 
PR72, is capable of dephosphorylating RB (Wlodarchak & Xing 2016) as well as 
the PP2A-B55α complex (Jayadeva et al. 2010). PP1 is also capable of partially 
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dephosphorylating and deactivating GWL during mitotic exit (Rogers et al. 
2016), and is able to dephosphorylate RB  (Kolupaeva & Janssens 2012; 
Kurimchak & Graña 2012; Hirschi et al. 2010; Wlodarchak & Xing 2016). 
Overall, the current consensus seems to be that PP1 is responsible for the 
complete dephosphorylation of RB after mitosis, whereas PP2A can be active 
throughout the cell cycle, dephosphorylating RB and p107/130 in response to 
various conditions (Kolupaeva & Janssens 2012; Kurimchak & Graña 2012; 
Wlodarchak & Xing 2016). Moreover, deregulated GWL would predominantly 
cause raised PP2A/B55 levels in late anaphase/early telophase, rather than in 
early G1, at a time when PP2A-B55 is already active. A synergy between GWL 
and CDK4 via PP2A-B55 would thus suggest that GWL function continues to be 
important beyond mitosis. This does not correlate with current models of GWL 
activation by mitotic CDK1, but agrees with the recent findings on S-phase 
functions of the GWL/ENSA pathway (Charrasse et al. 2017). 
 
Overall, a precise knowledge of the basic mechanism of the CDK4/GWL genetic 
interaction will be important both for our understanding of cell cycle control and 
for potential further clinical development of this synthetic lethality.  
 
6.2 The GWL-CDK4 synergy is not reversed by co-depletion of PP2A/B55  
The results described in the previous chapter could be regarded as 
controversial. So far, no other GWL substrates have been described and all 
phenotypes of GWL have been attributed to its phosphorylation of 
ENSA/ARPP19. However, GWL could have other substrates that have been 
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missed in previous screens or could also act in a kinase independent fashion. 
Nevertheless, GWL could still be impacting on PP2A-B55.  
 
A way to test PP2A involvement in the synergy between GWL and CDK4 would 
be to carry out double treatment targeting CDK4 and GWL and also PP2A-B55 
to see, if this rescues the S-phase population. Thus, I carried out siRNA 
knockdowns of the PP2A-B55α and δ subunits alongside shRNA-mediated 
knockdown of GWL and CDK4/6 inhibition. MDA-MB-231 shGWL cells were 
plated in cell culture and Dox added to knockdown GWL. 48 hours later, cells 
would be transfected with siCtrl or siB55α and siB55δ. Then 48 hours after 
siRNA transfection and 24 hours before cell harvesting, the 0.5 μM dose of 
Lee011/Ribociclib was added. This means that the cells were exposed to GWL 
shRNA for a total of 5 days, which is sufficient to deplete GWL (as shown in 
Chapter 3) and immunoblotting analysis showed a complete depletion of PP2A-
B55 α and δ after 72 hours of siRNA exposure. The immunoblots confirming the 
knockdown of GWL and PP2A-B55 α and δ are shown in Figure 6.1.  
 
Alongside the cells plated for the immunoblots, additional cells were plated and 
treated with the same protocol and were analysed by FACS with PI and EdU 
staining. On the day of cell harvesting, five days after plating, the cells were 
pulse labelled with 10 μM EdU for 1 hour before fixing and processing for 
FACS. The experiment was repeated three times in total, and the cell cycle 
phase population percentages were normalised as described in Chapter 4. A 
representative FACS plot, as well as the normalised cell cycle phase 




























Figure 6.1 Immunoblot to show the knockdown of GWL and PP2A-B55 
shGWL induced for a total of 5 days and siPP2A-B55α & δ induced for a total 
of three days prior to cell harvesting. A) Immunoblot of the first biological repli-
cate showing how GWL and PP2A-B55 can successfully be knocked down 






















































Fig. 6.2 Knockdown of PP2A-B55α and δ does not rescue MDA-MB-231 
cells from the Greatwall kinase and Cdk4/6 synergistic effect on the G1- 
and S-phase population MDA-MB-231 shGwl cells treated with 2 μM Dox for 
5 days and the indicated siRNA for 72 hours. In the final 24 hours, some cells 
were also treated with 0.5 μM Ribociclib/Lee011. A) Representative FACS plot 
B) Means of N=3 experiments normalised. Unpaired t-tests found no signifi-
cant differences between the cell cycle populations of the Ctrl si +Dox +Lee011 
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In Fig. 6.2, the phenotype in which the G1 population increases and the S 
population is significantly decreased that was shown in Chapter 4 is replicated 
in the Ctrl siRNA + Dox + Lee011 cells. When cells are also treated with siB55 
α and δ, the S-phase population is only marginally increased, and these 
changes are not statistically significant according to an unpaired t-test 
(GraphPad Prism analysis). 
 
6.3 The Greatwall-CDK4 synergy is recapitulated by ENSA/ARPP depletion 
To implicate PP2A inhibition in the CDK4 synergy we tested, we would see a 
similar synergy following depletion of the GWL substrates ENSA and ARPP19 
with siRNA. MDA-MB-231 cells were transfected with siCtrl or both siENSA and 
siARPP19 for a total of 72 hours. In the final 24 hours before cell harvesting, the 
0.5 μM dose of Lee011/Ribociclib was added. I did not treat the cells with Dox 
as this would have knocked down GWL upstream of ENSA/ARPP19 and the 
GWL-CDK4 synergy phenotype would be seen instead. The immunoblots 
showing the knockdown of ENSA across the three biological replicates are 
shown in Figure 6.3. A representative FACS plot for this experiment and the 
normalised cell cycle phase populations for the three replicates are shown in 
Figure 6.4. ENSA/ARPP19 depletion had only minor effects on the cell cycle 
profile of MDA-MB-231 cells resulting in a small increase in G2/M cells. 
Moreover, combined inhibition of CDK4 and ENSA/ARPP19 depletion did not 
show a significant decrease in the S-phase population, as previously observed 
in GWL depleted cells. This result suggests that GWL does not act in this 




Figure 6.3 Immunoblot to show the knockdown of ENSA shGWL induced 
for a total of 5 days and siENSA and siArpp19 induced for a total of three 
days prior to cell harvesting. A) Immunoblot of the first biological replicate 
showing how ENSA can successfully be knocked down  B) Immunoblot of the 






























Figure 6.4 Greatwall kinase/CDK4 synergy is not reversed by 
co-depletion of ENSA and Arpp19 siENSA and siArpp19 induced for 
a total of three days, and 24 hours treatement with 0.5 μM Riboci-
clib/Lee011 prior to cell harvesting. A) Representative FACS plot  B) 
Means of N=3 experiments normalised.
i) Ctrl si
ii) Ctrl si + 0.5 μM 
Lee011
iii) ENSA si and 
Arpp19 si
iii) ENSA si and 

























































This hints at an ENSA and ARPP19 independent function of GWL that pertains 
to the G1/S phase transition. 
 
6.4 Greatwall and CDK4 act in parallel on CDK2 activity in interphase cells 
To further investigate the mechanism of GWL and CDK4 synergy on S-phase 
progression we employed a single cell assay for CDK2 activity. This is based on 
work from the Meyer lab (Spencer et al. 2013) that reported a CDK2 probe 
based on cellular localisation. This fluorescent fusion protein is found in the 
cytoplasm when CDK2 activity is high, and in the nucleus when it is low. The 
ratio of nuclear and cytoplasmic signal is thus a direct read-out for CDK2 kinase 
activity. 
  
We obtained a lentiviral expression plasmid containing the DHB-Venus fusion 
protein from Sabrina Spencer and exchanged the Venus FP with mCherry to 
visualise the probe in our GFP expression shRNA cells. Stable cell lines were 
generated and incubated for 3 days with Dox to deplete GWL. We then added 
0.5 µM Lee01 and imaged the cells for 25 hours using the Operetta high-
throughput microscope. Figure 6.5A shows that GWL depletion alone has a 
significant effect on CDK2 activation following cytokinesis. However, the effect 
of CDK4 inhibition alone is more pronounced and comparable to the double 
treatment. It appears that there is an upward trend in CDK2 in activity in the 
CDK4 inhibited cells which is not present in the double treatment cells than in 
the later time points (around 10-14 hours post cytokinesis). However, this does 
not appear to be highly significant. Later time points may reveal a more 
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dramatic effect of the double treatment on CDK2 reactivation, compared to 
CDK4 inhibition on its own. 
 
There was, however a striking difference in the cells lacking both GWL and 
CDK4 activity. In Figure 6.5B, the levels of CDK2 activity are judged by eye 
and an example of this qualitative classification is shown in Figure 6.5C. The 
medium CDK2 activity is when there is no discernible difference in fluorescence 
between inside and outside the nucleus. High CDK2 activity is when the 
cytoplasm shows high fluorescence and there is no fluorescence in the nucleus. 
Low CDK2 activity is when the nucleus clearly shows higher fluorescence than 
the cytoplasm. Cells with high CDK2 activity were either undergoing mitosis and 
reverting to G1 or maintaining the CDK2-high state throughout the experiment. 
In the double inhibited cells, however, every single CDK2-high cell that we 
observed reverted to a CDK2-low state within 5-10 hours after CDK4 inhibition 
(Fig 6.5B).  
 
These data suggest that GWL and CDK4 collaborate to maintain a high CDK2 
activity throughout interphase. The mechanism of this interaction remains to be 
determined but is likely to involve RB phosphorylation. Indeed, previous work 
(K. E. Knudsen et al. 2000) has found that RB dephosphorylation in S-phase 
can cause a cell cycle exit, and that this frequently occurs in response to DNA 









Figure 6.5 Effects of GWL depletion and/or CDK4/6 inhibition 
on CDK2 activity  
A) CDK2 activity was quantified by measuring the ratio of mean 
cytoplasmic/mean nuclear fluorescent intensity of the 
DHB-mCherry probe. Each cell was followed in hourly intervals 
with the first timepoint co-inciding with cytokinesis.
B) Qualitative analysis of CDK2 activity in cells that showed high 
activity (cytoplasmic probe localistion at the onset of the experi-
ment. 
* indicates cells that revert from high to medium CDK2 activity. 
** indicates cells that revert to low CDK2 activity. 
C) Example of a Greatwall depleted cell following CDK4 inhibition 
that reverts to a CDK2-low state without intermittent mitosis. i) 
High CDK2 activity is when the cytoplasm shows high fluores-
cence and there is no fluorescence in the nucleus. ii) The medium 
CDK2 activity is when there is no discernable difference in fluo-
rescence between inside and outside the nucleus. iii) Low CDK2 





6.5 Conclusions and discussion 
This chapter attempted to elucidate the mechanism underpinning the synthetic 
lethality between GWL and CDK4 that has been observed in the TNBC cell line, 
MDA-MB-231. The most obvious first candidate would be that this mechanism 
is mediated by PP2A-B55. This theory being that if PP2A were responsible for 
inhibiting the activation of CDK4 and/or inhibiting the phosphorylation of RB, 
then GWL would be linked to CDK4 via its indirect regulation of PP2A-B55. 
However, when we knocked down the α and δ subunits of PP2A-B55, there was 
no rescue of the S phase population, indicating that another protein was 
keeping the cells in a G1-like state of arrest. Because GWL influences PP2A-
B55 activity via it’s known substrates, ENSA and ARPP19, if the knockdown of 
these proteins in combination with the CDK4/6 inhibition ameliorated the S 
phase population, then this would indicate that the BEG pathway (PP2A-
B55α/ENSA/GWL) is involved. 
 
Overall, the work in this chapter challenges the idea that GWL exclusively works 
in mitosis via its substrates ENSA and ARPP19 to inhibit PP2A-B55. Our 
findings point to an ENSA/ARPP19 independent role of the kinase in G1 and S-
phase in concert with CDK4. Given that these effects have been observed in 
RB positive cells and previous chapters showed the RB negative cell MDA-MB-
436 cells resistant to this treatment, it is likely that RB is the ultimate target of 
this pathway. Although, GWL could act on other aspects of CDK2 activity, such 
as Y15 dephosphorylation, or CKI stability. However, these effects should also 
be observable in RB negative cells.  
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GWL could be directly involved in RB phosphorylation, or act via regulating RB 
phosphatases. It is also possible that this new function does not depend on the 
GWL kinase activity but involves a kinase independent mechanism. Further 
work will be required to uncover how precisely CDK4 and GWL support each 





Chapter 7. General discussion and future directions 
 
The work presented here has focused on searching for a weakness in the 
armour of TNBC cells by examining the role of the mitotic kinase GWL. The use 
of a stable, Dox-inducible shRNA-mediated knockdown system allowed for 
flexible investigation of GWL depletion phenotypes in TNBC cells. Using this 
system, we found that GWL knockdown reduces cell proliferation, causes a 
reduction in the number of actively cycling cells (as shown by a reduction in the 
S phase population), and causes cells to exit the cell cycle and enter either 
senescence or quiescence, or commit apoptosis, probably following mitotic 
catastrophe. This data is largely in agreement with other works regarding GWL 
knockdown phenotypes (Álvarez-Fernández et al. 2013). However, we were 
surprised to find that the major consequence of loss of GWL in these cells 
appeared to be on the replicating cell population, and not on the progression 
through mitosis, which would have been the expected result. Another 
interesting part of our work, supported by the recent study from the Malumbres 
lab (Álvarez-Fernández, Sanz-Flores, Sanz-Castillo, Salazar-Roa, Partida, 
Zapatero-Solana, Ali, Manchado, Lowe, VanArsdale, Shields, Caldas, Quintela-
Fandino & Malumbres 2018b) is the different responses to GWL depletion in 
various cell types. To date, no GWL knockout cell line that is viable has been 
reported and it is likely that small amounts of the kinase are absolutely critical 
for mitotic function. However, cancer cells often have highly elevated levels of 
this protein and a subset of these cells has become very sensitive to 
perturbations of GWL activity. Clearly, we do not necessarily see a correlation 
between high expression and sensitivity (compare for example, the GWL levels 
 171 
observed in MDA-MB-231 and MDA-MB-436 cells). This makes it difficult to 
conclude on a presumptive ‘tumour driver’ function of GWL, and other 
biomarkers are urgently needed to predict sensitivity to GWL inhibition.  
 
The observed S phase defects described in Chapter 3 are a reduced number of 
EdU positive (S phase) cells as well as a reduction in the total mean EdU 
intensity, which indicates a reduced number of firing DNA replication forks. This 
is in contradiction with the study that found that total knockdown of GWL 
caused cells to arrest in G2, and partial knockdown caused arrest in 
prometaphase (summarised in Table 1.1) (Burgess et al. 2010). Though that 
study by the Castro group was carried out in HeLa (cervical cancer) cells, which 
may behave differently to breast cancer cell lines. A more careful analysis of 
this phenotype will be necessary to conclude on the exact effects of GWL on 
the replication machinery. However, the Castro study already provides a 
potential mechanism by suggesting Treslin stability as a potential target 
(Charrasse et al. 2017). Further work on this subject will require means to 
specifically inhibit GWL in interphase to rule out knock-on effects from 
segregation errors in the previous mitosis. Specific inhibitors of GWL would be 
useful, but combination of cell synchronisation and depletion may also be a 
potential way forward to further address this phenotype. A factor that is 
confounding efforts to synthesise selective and powerful GWL inhibitor 
molecules is the fact that no X-ray structures of full-length GWL are available. 
Although the amino acid sequence of GWL is highly related to the N- and C-
terminal kinase lobes of the MAST kinases (microtubule-associated 
serine/threonine kinase; MAST1, 2, 3 and 4) and other AGC kinases, GWL has 
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an unusual ~500 amino acid insertion between the DFG and APE motifs of the 
activation segment connecting the N- and C-terminal lobes - a feature which so 
far has prevented full-length crystallography of the protein (Blake-Hodek et al. 
2012; Ocasio et al. 2016). Given the lack of mechanistic insight in the observed 
S-phase defects in GWL depleted cells, we chose a genetic approach to further 
investigate this phenotype. This, a major part of this work was dedicated to 
finding and validating a synthetic lethality hit in combination with GWL 
depletion. This thesis shows for the first time a synthetic sensitivity relationship 
between the cell cycle kinases GWL and CDK4. This interaction was initially 
discovered in a siRNA and drug screen, and then validated in a panel of breast 
cells using shGWL and in MDA-MB-231 cells with inducible CRISPR-Cas9 
GWL knockout.  
 
Synthetic lethality is a well-established concept and should be based on careful 
quantification. Synergism can be defined as an effect that is more than additive, 
whereas antagonism is an effect that is less than additive (Chou 2006; 
Foucquier & Guedj 2015). The colony formation assays and EdU incorporation 
assays that I performed are not suitable to perform this type of classification, but 
just suggest an overall trend of synergy. As shown by the results in Chapter 5, 
GWL depletion has a noticeable deleterious effect on a cell type, and a low 
dose of CDK4/6 inhibitor alone (0.5 μM Ribociclib/Lee011 or 50 nM Palbociclib) 
has minimal effect. However in combination they have an effect that is greater 
than that of GWL depletion alone, so this effect could be described as 
enhancement or potentiation (Chou 2006). The observed effect could indeed be 
truly synergistic, but a different experimental set up would be needed to 
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determine if this is the case. Whilst the synthetic sensitivity observed in Chapter 
5 is very clear, as a next step, clonogenic assays should be designed with the 
Loewe or Bliss scoring systems in mind to assess the size of the effect caused 
by this combination treatment with GWL depletion and CDK4/6 inhibition. There 
are software packages available to calculate such scores, such as CompuSyn 
for the Loewe model (Chou 2006). Asghar and colleagues used the 
sulforhodamine B (SRB) cell viability assay and the Bliss addition score system 
to quantify at which doses and in which cell lines a CDK4/6 inhibitor and a PI3K 
inhibitor were acting in synergy (Asghar et al. 2017). 
 
It is striking that the observed effects of GWL and CDK4 are exclusive to an RB-
positive TNBC cell line, while not observed in an RB-negative cell line. This 
suggests that ultimately the effects of GWL on progression from G1 to S-phase 
are likely to occur on the level of RB phosphorylation. Initially we hypothesised 
that GWL could participate in this pathway via ENSA/ARPP19 dependent 
inhibition of PP2A-B55, for example by reducing the RB phosphatase activity. 
However, the results presented in Chapter 6 points to the surprising conclusion 
that the function of GWL does not rely on its canonical downstream target. 
Efficient depletion of ENSA/ARPP19 does not synergise with CDK4 inhibition, 
and PP2A-B55 subunit α and δ depletion does not prevent this synergy. It is 
thus tempting to speculate that GWL acts either via a novel substrate, or in a 
kinase independent manner in concert with CDK4. 
 
The final experiments of this thesis further substantiate our findings on a new 
GWL function in the G1/S phase of the cell cycle. We observe a clear effect of 
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GWL depletion on CDK2 reactivation in G1 phase. Moreover, cells that have 
already high CDK2 activity and are in late G1 or S phase revert back to a low 
CDK2 state after double kinase inhibition. A similar reversion of S phase was 
previously observed following RB dephosphorylation (K. E. Knudsen et al. 
2000). It could be speculated that GWL is required in cells that are RB positive 
and suffer from high replication stress to support CDK4 in maintaining RB 
phosphorylation and allow S phase progression. This is a testable hypothesis, 
and the further work that is required will be carried out by the Hochegger lab to 
further investigate this mechanism. Spencer and colleagues demonstrated that 
the bifurcation of cell fate into either a more proliferative or resting state after 
mitogen starvation is determined by the CDK inhibitor p21 (Spencer et al. 
2013). They used time-lapse microscopy, followed by fixed-cell immunostaining 
and a jitter-correction computer script to trace individual fixed, antibody-stained 
cells back to their corresponding live filmed cells. They found that high levels of 
p21 were responsible for causing a cell to enter the CDK2low state after mitosis 
(Spencer et al. 2013). A similar strategy could be used to work out what state 
the breast cancer cell lines enter after being treated with single and double 
treatments of GWL knockdown and CDK4/6 inhibitor by filming and 
immunostaining the cells for RB phosphorylation and p21. This could be done 
using the method outlined above (Spencer et al. 2013) or with flow cytometry if 
tracing individually back to each live cell was not deemed necessary. Cells 
could be fixed at various time points and then have their RB phosphorylation 
levels and/or p21 levels analysed with one of these methods. For example, 
antibodies (including fluorescent conjugates) to detect RB phosphorylation at 
Serine 807/811 are available, and so could be used in flow cytometry and 
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immunoblotting experiments to see if double treatment of GWL depletion and 
CDK4/6 inhibition causes a reduction in this RB phosphorylation. Including 
conditions with and without serum starvation could also be interesting. I would 
predict that since the majority of cells treated with both GWL shRNA and 
CDK4/6 inhibitor showed a low ratio of Cytoplasm/Nuclear DHB-mCherry probe, 
these cells would show hypo-phosphorylated RB, high p21 levels, and would 
not progress into S phase.  
 
The flow cytometry experiments in Chapters 5 and 6 show a large 
accumulation of cells that are apparently in G1 phase. This could be due to cell 
cycle arrest at G1, or perhaps exhaustion of S/G2/M phase cells due to cell 
death, and any remaining G1 cells might be still technically be cycling. In 
addition, because many previous studies of GWL depletion in human cells 
report mitotic defects (Table 1.1), as well as some observed cell death in the 
live cell imaging (Figures 3.9 and 3.10) some further experiments should be 
done to clearly determine if any of the observed phenotypes in this thesis are 
due to a mitotic arrest or mitotic catastrophe. Whilst classifying the cells by DNA 
content using PI staining in the flow cytometry experiments should distinguish 
between G1 and M cells, there is the possibility that many mitotic cells were 
lost. An issue with the flow cytometry experiments in this thesis is that the cell 
culture medium, which may have contained many dead and mitotic cells, was 
discarded during cell harvesting and fixation. To be more certain on the mitotic 
status of cells treated with both GWL shRNA and CDK4/6 inhibitor, some more 
live cell imaging and flow cytometry experiments should be done. Live cell 
imaging with fluorogenic cytoskeletal and DNA markers suitable for live cell 
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microscopy should be performed, such as SiR-tubulin and SiR-DNA. The 
microtubules, the doubled centrosomes and chromosomes behave very 
distinctively and uniquely during mitosis, and so mitotic phenotypes following 
synthetic sensitivity should be visible, if present.  Another method would be to 
analyse cyclin levels using flow cytometry, whilst also using PI staining for DNA 
content (Pozarowski & Darzynkiewicz 2004). As shown in Figure 1.1, Cyclin D1 
is expressed by some G1 cells as well as some cells entering and progressing 
through S phase, and most G2/M cells are Cyclin D1 negative. Cells express 
Cyclin A as they enter S phase, and maximally by G2 cells whereas mitotic cells 
(post-prometaphase) are Cyclin A negative. Cyclin B is expressed by late S 
cells, which peaks in G2/M. Mitotic cells should also not be expressing Cyclin E. 
Thus, staining cells for at least Cyclin B1 to detect mitotic cells, as well as one 
other to find some G1 cells such as Cyclin D1 (Pozarowski & Darzynkiewicz 
2004), whilst using treatments to deplete GWL and CDK4, should provide some 
resolution as to where in the cell cycle the affected cells are. 
 
In addition, experiments should be carried out for G1 arrest markers. The 
experiments of Chapters 5 and 6 ideally should be repeated and expanded as 
described below, including harvesting the original cell culture medium to 
analyse the cells within, which could include dead and mitotic cells. However, 
there is no singular marker for G1 arrest, and the cell cycle pathways are often 
disrupted in cancer cells and so a range of markers should be analysed. As 
mentioned in Chapter 5, time course immunoblots tracking the cell cycle status 
of the culture over several days could be performed. Then these immunoblots 
could be probed for multiple G1 arrest markers such as Cdt1, p53, p21, p27 
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and p16. Experiments probing for senescent cells could be done, such as a β-
galactosidase assay. Also, the fluorescent marker mVenus p27K− is able to 
label quiescent cells so this experiment could be done via IF microscopy (Oki 
et al. 2014). 
 
The inhibitors of CDK4 in clinical use also inhibit CDK6. It could be worth 
carrying out experiments comparing GWL depletion with siCDK6 and siCDK4 to 
see if there is any preferential effect between these two CDK enzymes. 
 
The synergy between GWL and CDK4 that is described in this thesis could one 
day have a significant clinical impact. It remains to be seen, if GWL inhibition 
will have an effect on cells that have acquired resistance to CDK4 inhibition. If 
the mechanism of resistance is loss of RB, then it is very unlikely that a 
beneficial therapeutic effect will emerge. However, RB independent 
mechanisms of CDK4 resistance, such as Cyclin E and E2F over-expression 
are frequently observed in cancer (E. S. Knudsen & Witkiewicz 2017) and so 
could be susceptible to combined GWL and CDK4 treatment. Until specific 
inhibitors of GWL are discovered, it might be beneficial to test the efficacy of 
PP2A activator drugs in combination with CDK4/6 inhibitors. A PP2A activating 
drug is almost the reflection of a GWL inhibitor, by promoting the phosphatase 
activity rather than shutting off its inhibition by GWL. FTY720 (also known as 
Fingolimod or Gilenya) is a PP2A activating drug in clinical use as an 
immunosuppressant for multiple sclerosis patients (Oaks et al. 2013), is gaining 
interest as a potential cancer therapeutic (Cristóbal et al. 2016) as well as PP2A 
activating compounds in general as an anti-cancer strategy. This is due to the 
 178 
known tumour suppressing effects of this phosphatase (C. M. O’Connor et al. 
2018; Janssens et al. 2005). Further work on acquired resistance will be 
necessary to gain more confidence in the therapeutic applicability of the 
findings presented here. The next steps to interrogate the clinical potential of 
targeting GWL and CDK4 simultaneously would be to evaluate tumour killing 
ability and toxicity in in vivo studies. MDA-MB-231 cells are commonly used in 
xenografts, so shRNA-containing cell lines could be grafted into mouse models, 
and appropriate doses of Dox and Palbociclib given to see if this causes tumour 
reduction. Measuring the effects of GWL depletion and CDK4 inhibition in 3D 
tumour models would also be beneficial, as cancer cells behave differently and 
in a more clinically relevant fashion in 3D. 3D cell cultures create an 
environment that is closer to in vivo than 2D cultures, and so the cells may 
behave and communicate differently. For example, there could be hypoxic cells 
in the centre of a 3D culture or organoid. Once GWL inhibitors are available, in 
vivo studies with patient-derived xenografts (PDX) should be tested in 
immunocompetent mice using combination treatments of GWL and CDK4/6 
inhibitors as this would provide toxicity data on the drug treatments, how the 
mammalian immune system reacts to the treatment, and patient-derived cells 
are more clinically relevant than cell lines. There is pre-clinical research that 
suggests CDK4/6 inhibition is beneficial for stimulating anti-tumour immune 
responses (Deng et al. 2018). 
 
The work presented here tells us that there is much more to be learned about 
the formerly elusive GWL from the perspectives of both basic and translational 
biology. Whilst the precise basis for the relationship between GWL and CDK4 







Appendix 1: Raw data from a small molecule drug screen using 
a panel of drugs on MDA-MB-231 shScr and shGWL cells 
treated with Dox. Drug names and their targets are listed in 
column headed ‘GeneID’ A) Drugs which displayed synthetic 
sensitivity with GWL. The CDK4/6 inhibitor Palbociclib is highlighted 
in yellow. B) Drugs which displayed synthetic resistance with GWL.  
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